

Perinatal Hepatitis B Prevention Program (PHBPP)

Michigan Perinatal Hepatitis B Prevention Program Staff:

Manager:	Patricia Vranesich	517-335-8159	vranesichp@michigan.gov
Coordinator:	Pat Fineis	517-335-9443	fineisp@michigan.gov
Surveillance Specialist:	Kari Tapley	313-456-4431	tapleyk@michigan.gov
Case Manager/SE MI:	Sallie Pray	313-456-4432	prays@michigan.gov
Case Manager/Out-state:	Marcy Smith	517-335-8122	smithm7@michigan.gov

Mission: To identify hepatitis B surface antigen-positive (HBsAg-positive) women

prenatally or at delivery for each pregnancy so that their infants, household and sexual contacts can be tested and treated to prevent the spread of the hepatitis B

virus (HBV).

Surveillance: Statewide, an average of 332 HBsAg-positive pregnant women is reported

annually. Based on Centers for Disease Control and Prevention (CDC) estimates,

396-597 HBsAg-positive pregnant women should be identified annually.

Prevention: Prevention of perinatal hepatitis B transmission requires the coordinated transfer of

information between laboratories, primary care providers, hospitals, and the

local/state health departments to ensure that all:

• Pregnant women are screened for HBsAg, all HBsAg-positive results are reported to the local health department (LHD) in the county where the patient resides within 24 hours, and the results are sent to the delivery hospital with the prenatal care record.

- Household and sexual contacts of HBsAg-positive pregnant women are identified, tested and immunized if susceptible.
- Infants of HBsAg-positive women receive appropriate prophylaxis and postvaccination serology.
- All infants receive the birth dose of hepB vaccine prior to hospital discharge.

To view the manual in its entirety or to obtain additional copies go to www.michigan.gov/hepatitisB.

See the 12/23/05 MMWR: "A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States" for the latest Advisory Committee on Immunization Practices (ACIP) recommendations, at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm.



Overview: Perinatal Hepatitis B Prevention Program (PHBPP)

If you work in a laboratory:

- Report all hepatitis B surface antigen-positive (HBsAg-positive) results to the local health department (LHD) in the county where the patient resides within 24 hours of discovery
- Report all HBsAg results to the ordering physician

If you provide prenatal care:

- Test every pregnant woman during each pregnancy for HBsAg
- Inform pregnant women of their HBsAg status
- Send copy of HBsAg test result for current pregnancy with prenatal records to delivery hospital
- Report all HBsAg-positive pregnant women to the LHD within 24 hours
- Counsel HBsAg-positive pregnant women about their status and refer for appropriate care
- Contact the pediatric provider to communicate the woman's HBsAg-positive status and the need for hepB vaccination and hepatitis B immune globulin (HBIG) for the infant
- Assess HBsAg-negative pregnant woman's risk for hepatitis B infection
- Counsel HBsAg-negative pregnant woman on methods to prevent hepatitis B transmission
- and vaccinate pregnant HBsAg-negative women if high risk
- Retest high risk pregnant HBsAg-negative women in their last trimester

If you work in the hospital labor and delivery unit or in the nursery unit:

- Review and record the maternal hepatitis B surface antigen (HBsAg) test result for the current pregnancy on both labor and delivery record and on infant's delivery summary sheet
 - If a woman presents with an unknown HBsAg status or with risk factors, test STAT
 - If STAT test is HBsAg-positive, report to the LHD within 24 hours
- Give all infants single-antigen hepB vaccine at birth
- Give all infants born to HBsAg-positive women single-antigen hepB vaccine and HBIG within 12 hours of birth
- Report administration of HBIG and hepB on the electronic birth certificate (EBC) worksheet
- Record the maternal HBsAg testing date and result on all newborn screening (NBS) cards
- Report all HBsAg-positive women and the HBIG and hepB administration to the PHBPP

If you provide pediatric care:

- Know the maternal HBsAg status for all infants to whom you provide care
- Complete the recommended hepB vaccine series and post-vaccination serology for all infants born to HBsAg-positive women
 - If infant is HBsAg <u>and</u> anti-HBs negative, repeat three doses of hepB vaccine and retest one month later
 - If the infant is HBsAg-positive, counsel the family and refer the infant for appropriate care
- Record vaccine administration in the Michigan Care Improvement Registry (MCIR)
- Report hepB administration and post-vaccination serology results to the PHBPP

If you provide health care to a contact of an HBsAg-positive woman:

- Identify, test and treat all household and sexual contacts of women who are HBsAg-positive
- Counsel HBsAg-positive contacts and refer them for appropriate care
- Give susceptible contacts three doses of hepB vaccine and complete post-vaccination serology
- Record vaccine administration in the Michigan Care Improvement Registry (MCIR)
- Report hepB administration and post-vaccination serology results to the PHBPP



Perinatal Hepatitis B Prevention Program (PHBPP) Services

Universal Hepatitis B Vaccination Program:

Hospitals who are enrolled in this program receive free hepatitis B vaccine to give to all infants at birth. This service acts as a "safety net" to prevent both horizontal and vertical transmission.

Hepatitis B vaccine and hepatitis B immune globulin (HBIG):

Infants, household and sexual contacts enrolled in the perinatal program are eligible for free hepatitis B vaccine, HBIG, and testing.

Free Hepatitis B test kits are available for:

- Pregnant women who do not have insurance or Medicaid, for the initial prenatal work-up and for re-testing if high risk
- Infants born to HBsAg-positive women after completion of the hepatitis B vaccine series
- Household and sexual contacts of HBsAg-positive pregnant women

Case management services:

Educational information, support and tracking are provided to ensure hepatitis B vaccine series completion and testing. These services are available to all infants, household and sexual contacts associated with the pregnant HBsAg-positive woman reported to the PHBPP.

Guide to Perinatal Hepatitis B Prevention:

A comprehensive manual is available at www.michigan.gov/hepatitisB with sections specifically designed for:

- Prenatal Care Providers
- Laboratories
- Hospitals
- Local Health Departments
- Family Practice Providers
- Pediatric Care Providers

Educational sessions:

- Perinatal Hepatitis B Prevention with 1.0 contact hours
- Hepatitis A-E with 1.5 contact hours
- Hepatitis A-E and post-exposure prophylaxis with 1.5 contact hours

If you have any questions, or for additional information on how to obtain these services contact the PHBPP staff at 517-335-8122 or 800-964-4487. In southeast Michigan, call 313-456-4431 or 313-456-4432.



Michigan Infant Dies from Perinatal Hepatitis B Virus (HBV) Infection

A three-month-old infant died from acute HBV infection due to an error in reporting. After a review of provider and hospital records, it was determined that the infant's mother was chronically infected with HBV and tested hepatitis B surface antigen-positive (HBsAg-positive) during her pregnancy. Unfortunately, the test results were not reported from the laboratory to the local health department (LHD), and the provider inaccurately reported the mother's results as HBsAg-negative to the delivery hospital.

Since the information from the prenatal care provider indicated that the infant's mother was negative for HBV, the infant did not receive hepB vaccine or hepatitis B immune globulin (HBIG) as recommended for all infants born to HBsAg-positive women. The infant became ill at three months of age and died less than two weeks later due to fulminant HBV infection.

This tragedy illustrates the necessity that all laboratories and ordering physicians comply with Michigan law. It is absolutely critical that every HBsAg-positive result for pregnant women is reported to the LHD and to the delivery hospital.

What Happens to Infants Born to HBsAg-positive Women?

WITHOUT HepB vaccine or HBIG:


- 90% will be at risk for chronic infection
- 25% of those infected will die due to chronic liver disease

WITH HepB vaccine alone in a 3 or 4 dose series started at birth:

• 70% - 95% will be protected from getting HBV infection

WITH HepB vaccine and HBIG started at birth:

• 80% - 95% will be protected from getting HBV infection



Michigan Department of Community Health

□ Births to HBsAg-positive women

HBIG & 3 by 8 months

HBIG & 3 by 12 months

□ Post serology



Table of Contents

Prevention:

- 1. Overview: What Hospitals Need to Know
- 2. Hospital Responsibilities for Pregnant Women & Babies
- 3. Delivery Hospital Policies and Procedures to Prevent Perinatal Hepatitis B Virus (HBV) Transmission
- 4. Guidelines for Standing Orders in Labor & Delivery and Nursery Units to Prevent Hepatitis B Virus Transmission to Newborns

Maternal:

- 5. Hepatitis B Facts: Testing and Vaccination
- 6. Reportable Diseases in Michigan (on back, Directory of MI Health Departments by County)
- 7. Vaccines to Consider for the Pregnant Woman
- 8. Injectable Vaccine Administration for Adults
- 9. Guide for Using Vaccine Administration Record for Adults
- 10. Vaccine Administration Record for Adults
- 11. Important Vaccine Information Statement (VIS) Facts

Infant:

- 12. Give the Birth Dose
- 13. Hepatitis B Vaccine and Hepatitis B Immune Globulin Administration for Infants
- 14. Recommended Dosages of Hepatitis B Vaccine and Hepatitis B Immune Globulin
- 15. Hepatitis B Vaccine: What You Need to Know-Vaccine Information Statement (VIS)
- 16. Important Vaccine Information Statement (VIS) Facts
- 17. Guide for Using Vaccine Administration Record for Children and Teens
- 18. Vaccine Administration Record for Children and Teens

Reporting:

- 19. Hepatitis B Perinatal Case Report-Infant/Contact Form
- 20. Submission of the Electronic Birth Certificate (EBC) Hospital Worksheet
- 21. Hospital Worksheet
- 22. Completing the Newborn Screening Card
- 23. Newborn Screening Card

Resources:

- 24. Can Hepatitis B Surface Antigen-Positive Women Breastfeed
- 25. Vaccine Storage Basics
- 26. Eligibility and Ordering Protocol: Hepatitis B Vaccine and Hepatitis B Immune Globulin
- 27. Special Purpose MI VFC/Immunization Programs (Universal Hepatitis B Vaccination Program for Newborns; Hospital Enrollment Form; Hospital Profile)
- 28. Countries with Moderate or High Rates of Hepatitis B
- 29. Free Immunization Brochures and Materials Order Form
- 30. Immunization Materials Order Form
- 31. Web Sites for Hepatitis Resources
- 32. Clear Insert
 - A. Recommended Immunization Schedule for Ages 0-6 Years and Ages 7-18 Years
 - B. Hepatitis B: What Parents Need to Know (Brochure)
 - C. Mothers (Yellow Card)
 - D. Important (Yellow Card; and on the back, To Health Care Providers)
 - E. Alert Sticker
 - F. State of Michigan Official Immunization Record (Green Card)
 - G. Adult Immunization Record (Yellow Immunization Card)



Overview: What Hospitals Need to Know

Disease Burden:

- 20,000 infants born annually to hepatitis B surface antigen-positive (HBsAg-positive) women in the United States*
- 1,000 infants chronically infected annually due to infected mothers not being identified and not receiving appropriate post-exposure prophylaxis at birth*
- 332 HBsAg-positive pregnant women reported annually in Michigan
- 396-597 HBsAg-positive pregnant women should be identified annually in Michigan

Prevention:

Prevention of perinatal hepatitis B transmission requires the coordinated transfer of information between laboratories, prenatal care providers, hospital staff, and the local/state health departments. All hospitals should implement policies and procedures which include standing orders to ensure that all:

Pregnant women:

- Have HBsAg laboratory results in their medical record
- With no HBsAg laboratory results for the current pregnancy are tested STAT
- Who have HBsAg-negative test results and are at risk for hepatitis B virus (HBV) infection are tested again at the time of hospital admission
- Who are HBsAg-positive are reported within 24 hours, after discovery or diagnosis, to the local health department
- Who are HBsAg-positive are reported to the Perinatal Hepatitis B Prevention Program (PHBPP)

Babies:


- Have documentation of maternal HBsAg test results in their medical record
- Born to HBsAg-positive women:
 - Receive and have documented administration of the hepatitis B (hepB) vaccine and hepatitis B immune globulin (HBIG) within 12 hours of birth in their medical record
 - Are reported to the PHBPP
 - Born to HBsAg-negative women receive hepB vaccine prior to hospital discharge
- Born to women with unknown HBsAg status receive hepB vaccine within 12 hours of birth and HBIG if their mother is found to be HBsAg-positive

1

^{*}Centers for Disease Control and Prevention (CDC) Guidelines for Viral Hepatitis Surveillance and Case Management, January 2005.



Hospital Responsibilities for Pregnant Women & Babies



2



Delivery Hospital Policies and Procedures to Prevent Perinatal Hepatitis B Virus (HBV) Transmission

At time of admission for delivery:

- Review the maternal hepatitis B surface antigen (HBsAg) test result from the current pregnancy for every pregnant woman.
- Record these maternal HBsAg test results on both labor and delivery record and on infant's delivery summary sheet.
- Perform HBsAg testing **STAT** on women who:
 - Do not have a documented HBsAg test result for this pregnancy, or
 - Tested HBsAg-negative prenatally and are at risk for hepatitis B virus (HBV) infection during pregnancy (e.g., an immigrant from an endemic area, more than one sex partner in the previous 6 months, evaluated or treated for a sexually transmitted disease, a partner of or a recent or current injection-drug user, a household or sexual contact of a HBsAg-positive person, incarcerated, hemodialysis patient), or
 - Had clinical hepatitis since previous testing.

After delivery:

HBsAg-positive mothers and their infants:

- Administer single-antigen hepatitis B (hepB) vaccine and hepatitis B immune globulin (HBIG) to all infants born to HBsAg-positive mothers within 12 hours after birth, and record date and time of administration of HBIG and hepB vaccine in infant's medical record.
- Submit a completed *Hepatitis B Perinatal Case Report-Infant/Contact* Form (DCH-0973, pg 19 of the Perinatal Hepatitis B Manual) to the Perinatal Hepatitis B Prevention Program.
- Provide information regarding hepatitis B to HBsAg-positive mothers, including:
 - Advice that they may breastfeed their infants upon delivery;
 - Modes of HBV transmission;
 - Need for vaccination of their susceptible household, sexual, and needle-sharing contacts;
 - Need for substance abuse treatment, if appropriate; and
 - Need for medical management and possible treatment for chronic HBV.

Mothers with unknown HBsAg status and their infants:

- Administer single-antigen hepB vaccine within 12 hours of birth, and record date and time of administration in the infant's medical record.
- Alert infant's pediatric health-care provider if an infant is discharged before the mother's HBsAg test result is available. If the mother is determined to be HBsAg-positive, HBIG should be administered to the infant as soon as possible, but no later than age 7 days.

All mothers and their infants:

- Administer a dose of single-antigen hepB vaccine to all infants weighing at least 2000 grams.
- Ensure that all mothers have been tested for HBsAg prenatally or at the time of admission for delivery and document test results.
- Record date and status of maternal HBsAg test results on Newborn Screening (NBS) Card.
- Record the administration date of the birth dose of hepB vaccine and/or HBIG on the *Electronic Birth Certificate (EBC) Hospital Worksheet*.
- Provide infant's immunization record to mother and remind her to take it to the infant's first pediatric health-care provider visit.

Adapted from MMWR 2005; 54 (No. RR-16): [Box 4, Pg 15].

Guidelines for Standing Orders in Labor & Delivery and Nursery Units to Prevent Hepatitis B Virus Transmission to Newborns

To obtain the Centers for Disease Control and Prevention (CDC) recommendations for preventing hepatitis B in infants, children, and adolescents, visit CDC's website at www.cdc.gov/mmwr/PDF/rr/rr5416.pdf

In December 2005, the Centers for Disease Control and Prevention (CDC) published updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for prevention of hepatitis B virus (HBV) infections in infants, children, and adolescents. The American Academy of Pediatrics, American Academy of Family Physicians, and American College of Obstetricians and Gynecologists have endorsed these recommendations. To obtain a copy, go to www.cdc.gov/mmwr/PDF/rr/rr5416.pdf.

CDC recommends that all delivery hospitals institute standing orders to ensure

- Administration of hepatitis B vaccine to all medically stable newborns weighing at least 2 kg (4.4 lb) at birth before discharge from the nursery.
- Identification of infants born to hepatitis B surface antigen (HB-sAg)-positive mothers and infants born to mothers with unknown HBsAg status and administration of appropriate immunoprophylaxis to these infants.

The guidance below has been developed to help your hospital establish standing orders in the labor and delivery and nursery units and has been reviewed by CDC staff for consistency with ACIP recommendations.

Labor and Delivery (L&D)

Upon admission, review the HBsAg¹ status of all pregnant women. You must review a copy of the mother's original laboratory report to verify that the correct test was performed during this pregnancy and to verify the test date. Do not rely on a transcribed test result!

For women with a documented HBsAg test result

- Place a copy of the original laboratory report of the mother's HBsAg¹ test result into (1) the mother's L&D record and (2) the infant's medical record.
- If the mother is HBsAg positive, alert the nursery staff.
- If the mother is HBsAg negative and is at risk for HBV infection during this pregnancy (e.g., had more than one sex partner in the previous 6 months; had an HBsAg-positive sex partner; had evaluation or treatment for a sexually transmitted disease; currently uses or recently used injection drugs), perform a repeat test for HBsAg. Instruct the laboratory to call L&D and the nursery with the HBsAg test result ASAP.

For women without a documented HBsAg test result

- Perform HBsAg¹ testing ASAP on women who do not have a documented HBsAg test result from the current pregnancy.
- Instruct the lab to call L&D and the nursery with the HBsAg test result ASAP.

Nursery

For all newborns

- Review a copy of the mother's original HBsAg¹ lab report. Provide appropriate management based on (1) the mother's HBsAg status and (2) the infant's birth weight. Manage those who weigh less than 2 kg differently from those who weigh 2 kg or more (see below and footnotes 2, 5, 6).
- Ensure that a copy of the original maternal HBsAg¹ laboratory report is in the infant's medical record.

For infants born to HBsAg-negative mothers

- Administer single-antigen hepatitis B vaccine (0.5 mL, IM) before discharge to all infants weighing at least 2 kg at birth. ^{2,3,4} Document the hepatitis B vaccine dose appropriately in the infant's medical record, including date and time of administration.
- Give the mother an immunization record card that includes the hepatitis B vaccination date, and explain the need for a complete hepatitis B vaccine series to fully protect her baby. Remind the mother to bring the card with her each time her baby sees a provider.

For infants born to mothers with unknown HBsAg status

- Administer single-antigen hepatitis B vaccine (0.5 mL, IM) within 12 hours of birth.^{3,5} Do not wait for test results to return before giving this dose of vaccine! Document the hepatitis B vaccine dose appropriately.
- Give the mother an immunization record card that includes the hepatitis B vaccination date. Explain the need for further doses to fully protect her baby. Remind the mother to bring the card with her each time her baby sees a provider.
- Confirm that the laboratory has received serum for the mother's HBsAg¹ test. Verify when the HBsAg result will be available and that it will be reported to L&D and the nursery ASAP. If the nursery does not receive the report at the expected time, call the laboratory for the result.
- If the mother's HBsAg¹ test result comes back positive
 - Administer hepatitis B immune globulin (HBIG 0.5 mL, IM) to the infant ASAP. Document the HBIG dose appropriately in the infant's medical record. There is little benefit in giving HBIG if more than 7 days have elapsed since birth.
 - Alert the mother's and infant's physician(s) of the test result.
 - Follow the instructions below for infants born to HBsAg-positive mothers.
- If the infant must be discharged before the HBsAg result is known
 - Document contact information for the parents (e.g., addresses,

(continued on next page)

- telephone numbers, emergency contacts) in case further treatment is needed.
- Obtain the name, address, and phone number of the mother's and the infant's healthcare provider.
- Notify the mother's and the infant's healthcare provider that the mother's HBsAg test result is pending.

For infants born to HBsAg-positive mothers

- Administer HBIG (0.5 mL, IM) and single-antigen hepatitis B vaccine^{3,6} (0.5 mL, IM) at separate injection sites within 12 hours of birth. Document the hepatitis B vaccine and HBIG doses appropriately in the infant's medical record, including date and time of administration.
- Give the mother an immunization record card that includes the date
 of the hepatitis B vaccine and HBIG doses, and explain the need
 for further doses of hepatitis B vaccine to fully protect her baby.
 Remind the mother to bring the card with her each time her baby
 sees a provider.
- Notify the local or state health department of the infant's birth and the date and time of administration of HBIG and hepatitis B vaccine doses.
- Obtain the name, address, and phone number of the infant's primary care provider. Notify the provider of the infant's birth, the date and time of HBIG and hepatitis B vaccine doses administered, and the importance of additional on-time vaccination and postvaccination testing of the infant for HBsAg and antibody to HBsAg after completion of the hepatitis B vaccine series.
- Provide advice to the mother. Tell her
 - About the importance of her infant completing the full hepatitis B vaccine series on schedule
 - About modes of HBV transmission and the need for vaccination of her susceptible household, sexual, and needle-sharing contacts

- That she may breast-feed her infant upon delivery, even before hepatitis B vaccine and HBIG are given
- That blood will need to be drawn from the infant after completion of the hepatitis B vaccine series at age 9–18 months to determine if the infant needs further management
- That she needs to have a medical evaluation for chronic hepatitis B, including an assessment of whether she is eligible for antiviral treatment

Footnotes

- 1. Be sure the correct test for HBsAg (hepatitis B surface antigen) was/is ordered. The HBsAg test should not be confused with other hepatitis B serologic tests, including antibody to HBsAg (anti-HBs or HBsAb) and antibody to hepatitis B core antigen (anti-HBc or HBcAb).
- 2. Infants weighing less than 2 kg whose mothers are documented to be HBsAg negative should receive the first dose of vaccine 1 month after birth or at hospital discharge. The mother's HBsAg status must be part of the infant's medical record.
- 3. Federal law requires that you give parents a Hepatitis B Vaccine Information Statement (VIS) before vaccine administration. To obtain a VIS, download from the IAC website at www.immunize.org/vis or call your state health department.
- 4. Exceptions to giving the birth dose of hepatitis B vaccine are allowed on a case-bycase basis and only in rare circumstances. If a birth dose is not administered, a copy
 of the mother's negative HBsAg test result from the current pregnancy must be placed
 in the infant's medical record and the attending physician must write a specific order
 directing staff not to administer the birth dose in the hospital.
- 5. An infant weighing less than 2 kg whose mother's HBsAg status is unknown should receive HBIG and hepatitis B vaccine within 12 hours of birth. Do not count the hepatitis B vaccine dose as the first dose in the vaccine series. Reinitiate the full hepatitis B vaccine series at age 1–2 months.
- 6. An infant weighing less than 2 kg whose mother is HBsAg positive should receive the first dose of hepatitis B vaccine and HBIG within 12 hours of birth. Do not count the hepatitis B vaccine dose as the first dose in the vaccine series. Reinitiate the full hepatitis B vaccine series at age 1–2 months.

To access a CDC web page that includes a text version of the recommendations, a "Dear Colleague" letter that explains details of the recommendations, an archived net conference, brochures, slide sets, and more, go to: www.cdc.gov/ncidod/diseases/hepatitis/b/acip.htm

Hepatitis B Facts: Testing and Vaccination

— Who should be vaccinated? —

The following persons should receive routine hepatitis B vaccination according to the Centers for Disease Control and Prevention (CDC):

Routine vaccination:

- · All newborns at birth prior to hospital discharge
- All children and teens ages 0 through 18 years
- All persons who wish to be protected from hepatitis B virus (HBV) infection. CDC states it is not necessary for the patient to disclose a risk factor in order to receive hepatitis B vaccine.

Persons who are at risk for sexual exposure:

- Sexually active persons who are not in long-term mutually monogamous relationships
- Sex partners of HBsAg-positive persons
- Persons seeking evaluation or treatment for an STD
- Men who have sex with men

Persons at risk for infection by percutaneous or mucosal exposure to blood:

- Current or recent injection-drug users
- Household contacts of HBsAg-positive persons
- Residents and staff of facilities for developmentally challenged persons
- Healthcare and public safety workers with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids
- Persons with end-stage renal disease and those receiving dialysis.

Others:

- Travelers to areas with moderate or high rates of HBV infection
- Persons with chronic (life-long) liver disease
- Persons with HIV infection

All refugees, immigrants, and adoptees from countries with moderate or high rates of HBV infection should be screened. Adults should discuss their need or desire for hepatitis B vaccination with their healthcare providers.

— Hepatitis B lab nomenclature —

HBsAg: *Hepatitis B surface antigen* is a marker of infectivity. Its presence indicates either acute or chronic HBV infection.

anti-HBs: Antibody to hepatitis B surface antigen is a marker of immunity. Its presence indicates an immune response to HBV infection, an immune response to vaccination, or the presence of passively acquired antibody. (It is also known as **HBsAb**, but this abbreviation is best avoided since it is often confused with abbreviations such as HBsAg.)

anti-HBc (total): Antibody to hepatitis B core antigen is a nonspecific marker of acute, chronic, or resolved HBV infection. It is not a marker of vaccine-induced immunity. It may be used in prevaccination testing to determine previous exposure to HBV infection. (It is also known as HBcAb, but this abbreviation is best avoided since it is often confused with other abbreviations.)

IgM anti-HBc: *IgM antibody subclass of anti-HBc.* Positivity indicates recent infection with HBV (within the past 6 mos). Its presence indicates acute infection.

HBeAg: *Hepatitis B "e" antigen* is a marker of a high degree of HBV infectivity, and it correlates with a high level of HBV replication. It is primarily used to help determine the clinical management of patients with chronic HBV infection.

Anti-HBe: Antibody to hepatitis B "e" antigen may be present in an infected or immune person. In persons with chronic HBV infection, its presence suggests a low viral titer and a low degree of infectivity.

HBV-DNA: *HBV Deoxyribonucleic acid* is a marker of viral replication. It correlates well with infectivity. It is used to assess and monitor the treatment of patients with chronic HBV infection.

— Screening before vaccination —

Serologic testing prior to vaccination may be undertaken based on your assessment of your patient's level of risk and your or your patient's need for definitive information (see information in the left column). If you decide to test, draw the blood first, and then give the first dose of vaccine at the same office visit. Vaccination can then be continued, if needed, based on the results of the tests. If you are not sure who needs hepatitis B screening, consult your state or local health department.

Tests	Results	Interpretation	Vaccinate?
HBsAg anti-HBc anti-HBs	negative negative negative	susceptible	vaccinate if indicated
HBsAg anti-HBc anti-HBs	negative negative positive with ≥ 10mIU/mL*	immune due to vaccina- tion	no vaccination necessary
HBsAg anti-HBc anti-HBs	negative positive positive	immune due to natural infection	no vaccination necessary
HBsAg anti-HBc IgM anti-HBc anti-HBs	positive positive positive negative	acutely infected	no vaccination necessary
HBsAg anti-HBc IgM anti-HBc anti-HBs	positive positive negative negative	chronically infected	no vaccination necessary (may need treatment)
HBsAg anti-HBc anti-HBs	negative positive negative	four interpretations possible [†]	use clinical judgment

*Postvaccination testing, when it is recommended, should be performed 1–2 months after the last dose of vaccine. Infants born to HBsAg-positive mothers should be tested 3–9 months after the last dose of vaccine.

- [†]1. May be recovering from acute HBV infection
- May be distantly immune, but the test may not be sensitive enough to detect a very low level of anti-HBs in serum
- 3. May be susceptible with a false positive anti-HBc
- 4. May be chronically infected and have an undetectable level of HBsAg present in the serum

Managing chronic HBV infection —

When you identify a patient who is chronically infected with HBV, make sure you consult a specialist knowledgeable in the treatment of liver disease so your patient's care is optimized. Chronically infected persons need medical evaluation every 6–12 months to assess the status of their liver health and their need for antiviral therapy, as well as to screen for liver cancer. Persons with HBV infection should also be educated about their disease and how to protect others.

Household members and sex partners should be tested for HBV infection and given the first dose of hepatitis B vaccine at the same visit. (Vaccinating a person who has already been infected will do no harm). If testing indicates HBV susceptibility, complete the hepatitis B vaccination series. If testing indicates HBV infection, consultation and further care with a physician knowledgeable about chronic hepatitis B is needed.

www.immunize.org/catg.d/p2110.pdf • Item #P2110 (1/07)

REPORTABLE DISEASES IN MICHIGAN

A Guide for Physicians, Health Care Providers and Laboratories

The following is a list of conditions that should be reported to the local health department without delay if the agent is identified by clinical diagnosis, direct examination, culture, serology, molecular techniques or by histopathology.

Acquired Immunodeficiency Syndrome (AIDS)

Avian influenza

Bacillus anthracis (Anthrax)

Blastomyces dermatitidis

Bordetella pertussis (**Pertussis**)

Borrelia burgdorferi (**Lyme Disease**)

Brucella species

Burkholderia pseudomallei

Burkholderia mallei

Calymmatobacterium granulomatis

Campylobacter jejuni

Chlamydia psittaci (**Psittacosis**)

Chlamydia trachomatis (**Genital infections**), (**LGV**)

Chlamydia trachomatis (**Trachoma**)

Clostridium botulinum (Botulism)

Clostridium tetani (**Tetanus**)

Coccidioides immitis (**Coccidioidomycosis**)

Corynebacterium diphtheriae (**Diphtheria**)

Coxiella burnetii (Q Fever)

Cryptococcus neoformans

Cryptosporidium species

Cyclospora species

Dengue virus

Ehrlichia species

Encephalitis, viral

California serogroup

Eastern Equine

Powassan

St. Louis

Western Equine

West Nile

Unspecified

Entamoeba histolytica (Amebiasis)

Escherichia coli, O157:H7 and all other shiga toxin

positive serotypes

Francisella tularensis (Tularemia)

Giardia lamblia

Guillain-Barre Syndrome

Haemophilus ducreyi (**Chancroid**)

Haemophilus influenzae, <15 years of age, sterile site

Hantavirus

Hemolytic Uremic Syndrome (**HUS**)

Hemorrhagic fever viruses

Hepatitis, viral

Hepatitis A virus, (Anti-HAV IgM)

Hepatitis B virus, (**HBsAg**)

within 24 hours on pregnant women

Hepatitis C virus, (Anti-HCV)

Hepatitis, non-ABC

Histoplasma capsulatum

HIV, (Confirmed positive HIV serology and detection tests; CD4 counts/percents and all viral loads on people already known to be infected)

Influenza virus (Weekly aggregate counts)

Kawasaki Disease

Leptospira species

Legionella species

Listeria monocytogenes

Meningitis, viral

Meningitis, bacterial

Measles virus (Rubeola)

Mumps virus

Mycobacterium bovis

Mycobacterium leprae (**Leprosy**)

Mycobacterium tuberculosis (Tuberculosis)

Neisseria gonorrhoeae (**Gonorrhea**)

Neisseria meningitidis, sterile sites (Meningococcal Disease)

Orthopox viruses (Smallpox, Monkeypox)

Poliovirus

Plasmodium species (Malaria)

Rabies virus

Reye's Syndrome

Rheumatic fever

Rickettsia rickettsii (Rocky Mountain Spotted Fever)

Rickettsia species (Typhus Group)

Rubella virus

Salmonella species

Salmonella Typhi (Typhoid Fever)

Severe Acute Respiratory Syndrome (SARS)

Shigella species

Spongioform Encephalopathy (Includes CJD)

Staphylococcus aureus, vancomycin intermediate/

resistant (VISA/VRSA)

Staphylococcus aureus, (MRSA), outbreaks only

Streptococcus pyogenes, group A, sterile sites

Streptococcus pneumoniae, sterile sites, susceptible/ resistant

Toxic Shock Syndrome

Treponema pallidum (**Syphilis**)

Trichinella spiralis (**Trichinosis**)

Varicella (**Chickenpox**)

Vibrio cholerae (Cholera)

Yellow fever virus

Yersinia enterocolitica

Yersinia pestis (Plague)

LEGEND

Green Bold Text = An isolate or serum sample, where appropriate, is to be submitted to MDCH laboratory.

Report All Listed Conditions to the Local Health Department (see reverse) This reporting is expressly allowed under HIPAA Communicable Disease Rules: R 325.171, 172, 173

DIRECTORY OF MICHIGAN HEALTH DEPARTMENTS BY COUNTY

In general, health care providers should seek consultation regarding communicable disease

prevention and control services through their local health department.

Please check your phone directory to see if there is a branch office in your community if the number listed is long distance. Write that number here:

HEALTH DEPT.	COUNTY OFFICE	AREA	PHONE	FAX	COUNTY	HEALTH DEPT.	COUNTY OFFICE	AREA	PHONE	FAX
Ξ 2	Harrisville	686	724-6757	724-9975	10010	2	100000	010	745 5037	667 600
Ā	Allegan	269	5673-5411	673-2163	Leelanan	Lapter Co Benzie-Leelanan	Lapeer Ek Leelanan	231	256-0210	256-7399
ΑIΓ	Alpena	686	356-4507	354-0855	Lenawee	Lenawee County	Adrian	517	264-5234	264-0790
Bell	Bellaire	231	533-8670	547-0460	Livingston	Livingston County	Howell	517	546-9850	545-9685
Stan	Standish	686	846-6541	846-0431	Luce	LMAS DHD	Newberry	906	293-5107	293-5453
Haı	Hancock	906	524-6142	524-6144	Mackinac	LMAS DHD	St. Ignace	906	643-1100x14	643-7719
Has	Hastings	569	945-9516x114	945-2413	Macomb	Macomb County	Mt. Clemens	286	783-8190	493-0075
Bay	Bay City	686	895-4003	895-2083	Manistee	District #10	Manistee	231	723-3595	723-1477
Ben	Benzonia	231	256-0210	882-0143	Marquette	Marquette County	Negaunee	906	475-7844x23	475-4435
Ben	Benton Harbor	569	927-5627	926-8129	Mason	District #10	Ludington	231	845-7381	845-9374
Colc	Coldwater	517	279-9561	278-2923	Mecosta	District #10	Big Rapids	231	592-0130	592-9464
Batt	Battle Creek	569	969-6334	969-6488	Menominee	Delta/Men Dist	Menominee	906	863-4451	863-7142
Cass	Cassopolis	569	445-5280	445-5278	Midland	Midland County	Midland	686	832-6666	837-6524
Cha	Charlevoix	231	547-6523	547-0460	Missaukee	District #10	Lake City	231	839-7167	839-7908
Chel	Cheboygan	231	627-8850	627-9466	Monroe	Monroe County	Monroe	734	240-7832	240-7906
Saul	Sault Ste. Marie	906	635-3577	635-7081	Montcalm	Mid-Mich DHD	Stanton	686	831-3615	831-3666
Har	Harrison	686	539-6731	539-4449	Montmorency	District 4	Atlanta	686	785-4428	785-2217
St. J	St. Johns	686	227-3111	227-3126	Muskegon	Muskegon Co	Muskegon	231	724-4421	724-1325
Gray	Grayling	686	348-7800	348-5346	Newaygo	District 10	White Cloud	231	689-7300	689-5295
Esca	Escanaba	906	786-4111	786-7004	Oakland	Oakland County	Pontiac	248	858-1286	858-0178
Iron	Iron River	906	774-1868	265-4174	Oceana	District 10	Hart	231	873-2193	873-4248
Cha	Charlotte	517	541-2641	541-2666	Ogemaw	District 2	West Branch	686	345-5020	345-1996
Peto	Petoskey	231	347-6014	547-0460	Ontonagon	Western UP Dist	Ontonagon	906	884-4096	884-2358
Flint		810	257-1017	257-3247	Osceola	Cent MI Dist	Reed City	231	832-5532	832-1020
Gladwin	win	686	426-9431	426-6952	Oscoda	District 2	Mio	686	826-3970	826-5386
Bess	Bessemer	906	667-0200	667-0020	Otsego	NW MI Dist	Gaylord	686	732-1794	231-547-0460
Trav	Fraverse City	231	922-2718	922-2719	Ottawa	Ottawa County	Holland	616	396-5266	393-5659
Ithaca	g.	686	875-1019	875-1032	Pres. Isle	District 4	Rogers City	686	734-4723	734-3866
Hills	Hillsdale	517	437-7395x200	437-0166	Roscommon	Cent MI Dist	Prudenville	686	366-9166	366-8921
Han	Hancock	906	482-7382	482-9410	Saginaw	Saginaw Co	Saginaw	686	758-3887	758-3888
Bad	Bad Axe	686	269-9721	269-4181	St. Clair	St. Clair Co	Port Huron	810	987-5729	985-4340
Lan	Lansing	517	887-4308	887-4379	St. Joseph	Branch/Hills/St Jo	Three Rivers	569	273-2161x200	273-2452
Ionia	-	919	527-5339	527-8208	St. Joseph	Branch/Hills/St.Jo	Sturgis	569	659-4013x200	651-6090
Taw	Ta was City	686	362-6183	362-7181	Sanilac	Sanilac	Sandusky	810	648-4098	648-5806
Stan	Stambaugh	906	265-9913	265-4174	Schoolcraft	LMAS DHD	Manistique	906	341-6951	341-5230
Mt.	Mt. Pleasant	686	773-5921	773-4319	Shiawassee	Shiawassee Co	Corunna	686	743-2356	743-2362
Jacl	Jackson	517	768-1664	788-4256	Tuscola	Tuscola Co	Caro	686	673-8114	673-7490
Kal	Kalamazoo	569	373-5267	373-5060	Van Buren	VanBur-Cass DHD	Hartford	569	621-3143	621-2725
Kal	Kalkaska	231	258-8669	258-2805	Washtenaw	Washtenaw Co	Ypsilanti	734	544-6770	544-6706
Gra	Grand Rapids	616	632-7228	632-7085	Wayne (out-Wayne)	Wayne Co	Wayne	734	727-7078	727-7083
Haı	Hancock	906	482-7382	482-9410	Detroit	Detroit City	Detroit	313	876-4138	876-0070
Bal	Baldwin	231	745-4663	745-2501	Wexford	District 10	Cadillac	231	775-9942	775-4127



Vaccines to Consider for the Pregnant Woman

Trivalent (Inactivated) Influenza Vaccine (TIV)

The ACIP* recommends that due to increased risk for influenza-related complications, women who will be pregnant during the influenza season should be vaccinated. Vaccination can occur in any trimester. Researchers estimate that an average of 1-2 hospitalizations can be prevented for every 1,000 pregnant women vaccinated. One study of influenza vaccination of more than 2,000 pregnant women demonstrated no adverse fetal effects associated with influenza vaccine. It has been reported that only 12% of pregnant women, with no additional risk factor, receive TIV during their pregnancy.

Hepatitis B Vaccine (hep B)

The vaccine contains noninfectious hepatitis B surface antigen (HBsAg) particles and should cause no risk to the fetus. Hepatitis B virus infection affecting a pregnant woman may result in severe disease for the mother and chronic infection for the newborn. **Therefore, neither pregnancy nor lactation should be considered a contraindication to vaccination.**

Tetanus/Diphtheria Vaccine (Td) and Tetanus/Diphtheria/Pertussis Vaccine (Tdap)

ACIP recommends Td when tetanus and diphtheria protection is required during pregnancy. In some situations**, health care providers can choose to administer Tdap instead of Td to add protection against pertussis. When Td or Tdap is given during pregnancy, the 2nd or 3rd trimester is preferred. Pregnancy is not a contraindication for use of Tdap. Outcomes of pregnancy, data on safety, and the immunogenicity are not available for pregnant women who receive Tdap. When Tdap is administered during pregnancy, transplacental maternal antibodies might protect the infant against pertussis in early life. They also could interfere with the infant's immune response to infant doses of DTaP, and leave the infant less well protected against pertussis.

Pneumococcal Polysaccharide Vaccine (PPV23)

PPV23 is recommended for pregnant women with a high-risk condition.

The safety of pneumococcal polysaccharide vaccine during the 1st trimester of pregnancy has not been evaluated. No adverse consequences have been reported among newborns whose mothers were inadvertently vaccinated during pregnancy.

Hepatitis A Vaccine (hep A)

The safety of hep A vaccination during pregnancy has not been determined. However, because it is an inactivated vaccine, theoretical risk to the fetus is low. The risk associated with vaccination should be weighed against the risk of HAV infection.

Vaccines to Avoid During Pregnancy

Live, Attenuated Influenza Vaccine (LAIV)

The ACIP recommendations state that pregnant women should not be vaccinated with LAIV. (These persons should receive inactivated influenza vaccine)

Human Papillomavirus Vaccine (HPV4)

There has only been limited information about vaccine safety among pregnant women and their unborn babies. So far, studies suggest that the vaccine has not caused health problems during pregnancy, nor has it caused health problems for the child. But more research is still needed. For now, **pregnant women should wait to complete their pregnancy before getting HPV4 vaccine.** If a vaccine dose was inadvertently given during pregnancy, there is no indication for medical intervention. Complete the vaccine series when the woman is no longer pregnant.

Measles, Mumps, Rubella (MMR)

Measles, mumps, rubella (MMR) vaccine and its component vaccines should not be administered to women known to be pregnant. Because a risk to the fetus from administration of these live virus vaccines cannot be excluded for theoretical reasons, women should be counseled to avoid becoming pregnant for 4 weeks after vaccination with measles or mumps vaccines, or MMR or other rubella-containing vaccines.

Varicella (VAR) and Herpes Zoster (Zoster)

The effect of varicella virus and herpes zoster vaccine on the fetus is unknown; therefore, **pregnant women should not be vaccinated**. Non-pregnant women who are vaccinated should avoid becoming pregnant for 4 weeks following varicella vaccination. At this time, FDA guidelines recommend waiting 3 months between zoster vaccination and pregnancy.

^{*} ACIP = Advisory Committee on Immunization Practices

^{**}Prevention of Tetanus, Diphtheria and Pertussis among Pregnant Women: Provisional ACIP Recommendations for the Use of Tdap Vaccine, August 1, 2006 Refer to CDC website at www.cdc.gov/nip/acip for additional information and specific use during pregnancy included in the provisional and final ACIP recommendations on the above vaccines



Injectable Vaccine Administration for Adults*

Janet Olszewski, Director					
Vaccine	Age/Reminders	Route	Site	Needle Size	Contraindications [†]
Tetanus/Diphtheria (Td)	7 years & older	MI	Delfoid	1" – 1.5"	Anaphylactic reaction to prior dose or component; For Tdap: encephalopathy
Td with pertussis (Tdap)	11-64 yrs (Adacel®) 10-18 yrs (Boostrix®)			22-25g	within 7 days of previous pertussis vaccine dose without other known cause
Hepatitis B (hep B)	3-dose series; no booster recommended	IM	Deltoid	1" – 1.5" 22-25g	Anaphylactic reaction to prior dose or component (baker's yeast)
Hepatitis A (hep A)	2-dose series; 2^{nd} dose 6 mo after 1st	IM	Deltoid	1" – 1.5" 22-25g	Anaphylactic reaction to prior dose or component; hypersensitivity to alum (Havrix® only: 2-phenoxyethanol)
Measles/Mumps/Rubella (MMR)	Born 1957 or later, assure 1 dose given; 2 doses for high risk	SC	Lateral Upper Arm	5/8" 23-25g	Anaphylactic reaction to prior dose or component (neomycin, gelatin); pregnancy
Varicella (Var)	Born 1980 or later, assure 2 doses or evidence of immunity	SC	Lateral Upper Arm	5/8" 23-25g	Anaphylactic reaction to prior dose or component (neomycin, gelatin); pregnancy
Inactivated Influenza (TIV)	Given yearly (thru March)	IM	Deltoid	1" – 1.5" 22-25g	Anaphylactic reaction to prior dose or component (eggs)
Pneumococcal	No more than 2 lifetime doses	SC	Lateral Upper Arm	5/8" 23-25 g	Anaphylactic reaction to prior dose or
Polysaccharide (PPV 23)	Space at least 5 years apart	IM	Deltoid	1"-1.5" 22-25g	component
Meningococcal Conjugate (MCV4)	Adolescents & persons at risk age 11-55; 1 dose	IM	Deltoid	1" – 1.5" 22-25g	Anaphylactic reaction to prior dose or component
Human papillomavirus (HPV4)	Females age 9-26; 3-dose series	IM	Deltoid	1" – 1.5" 22-25g	Anaphylactic reaction to prior dose or component; hypersensitivity baker's yeast
Herpes Zoster (zoster)	Adults 60 years and older	SC	Lateral Upper Arm	5/8" 23-25 g	Anaphylactic reaction to prior dose or component (neomycin, gelatin); pregnancy
* Routinely screen for and administ	ter these vaccines as needed. See A	dult Immuniz	zation Schedule for add	litional information on	* Routinely screen for and administer these vaccines as needed. See Adult Immunization Schedule for additional information on risk groups, dosing and minimum intervals.

Routinely screen for and administer these vaccines as needed. See Adult Immunization Schedule for additional information on risk groups, dosing and minimum intervals. For travel and select-group vaccine information (IPV, yellow fever, rabies, etc.), refer to www.cdc.gov/nip

[†] Vaccines should never be administered in the buttocks. See package insert for complete contraindication/component listing; components may vary by brand of vaccine

8

December 19, 2

Vaccine Administration Record for Adults

Patient Name:	
Date of Birth:	
MCIR ID#	

Clinic Name/Address

Guide for Using This Form

Vaccine	Date Vaccine & Vaccine Information Statement Given	Type of Vaccine	Date on Vaccine Information Statement (VIS)	Vaccine Manf.	Vaccine Lot Number	-	Site Given ²	Route ³	Signature of Vaccine Administrator	Client Status ⁴
Tetanus, diphtheria	01/12/89 *	Td								
Td with acellular pertussis	04/25/99*	Td				ı				
	07/06/06*	Tdap			es vaccine					
Types are:		1	giv	en elsev	vhere					
Tdap										
Hepatitis B	10/2/02	НерВ-НерА	7/11/01	GSK	НАВ239А4		RA	IМ	Sally Smith RN	\mathcal{P}
Types are: HepB	11/12/02	НерВ-НерА	7/11/01	GSK	НАВ239А4		RA	IМ	Sally Smith RN	Р
HepB-HepA	08/04/03	НерВ-НерА	7/11/01	SSK.	НАВ239А4		RA	IМ	Jane Doe, MA	\mathcal{P}
Measles, Mumps, Rubella	10/2/02	MMR	06/13/02	MRX	M23456a		LA	SC	Sally Smith RN	\mathcal{P}
Type is: MMR	11/12/02	MMR	06/13/02	MRK	M23456a		LA	SC	Sally Smith RN	\mathcal{P}
Varicella	History	12/03/89							J 55	
Type is: Var	of disease	\								
Influenza	11/12/03	TNV	5/6/03	AVP	U088211		RA	IМ	Sally Smith RN	\mathcal{P}
Types are:	11/12/03						261		emigemm -g c	
TIV (Injectable)										
LAIV (Nasal)		disease h	nts varicella nistory	1			·	// D		
(See Back for Additional Spaces)		discuse i	listory				me shot different			
Pneumococcal										
Type is: PPV23										
Hanadilla A	10/2/02	НерВ-НерА	8/25/98	GSK	НАВ239А4		Ø.a.	IМ	Sally Smith RN	\mathcal{P}
Hepatitis A Types are: HepA	, , , , , , , , , , , , , , , , , , ,		, , ,	GSK	НАВ239А4		RA	IM	Sally Smith RN	\mathcal{P}
HepB-HepA	11/12/02	НерВ-НерА НерВ-НерА	8/25/98 8/25/98	GSK	НАВ239А4		RA	IM	Jane Doe MA	\mathcal{P}
Meningococcal	08/04/03	sup supst	0/23/30	9520	7515233711		RA		June Dee Jibt	
Types are: MCV4 MPSV4										
Human Papillomavirus										
Type: HPV4			How t	to comp	olete the ad	lmini	istratio	n recor	d for:	
			- Sin	gle vac	cines (thos	se wi	ith one	VIS)		
Zoster Type; Zoster				_	•			-	e than one VIS),	
			- Vad	ccines t	hat are giv	en e	Isewhe	re, and	•	
Other Other	+		∦ - His	tory of	chickenpo	x dis	sease			
Other	+		H							\bot
Other							İ			İ

¹ Place an asterisk (*) next to the date the vaccine was given to indicate vaccines administered elsewhere ² Site Code: LA=LT ARM, RA=RT ARM, LL=LT LEG, RL=RT LEG, and Nasal

³ Route Code: IM=intramuscular, SC=subcutaneous, and intranasal
⁴ Client VFC Status: M=Medicaid, U=Uninsured, D=Underinsured, A=American Indian or Alaskan Native, P=Private Insurance, See the most recent AIM Kit for updates

Vaccine Administration Record for Adults Clinic Name/Address Patient Name: Date of Birth: MCIR ID

Vaccine	Date Vaccine & Vaccine Information Statement Given	Type of Vaccine	Date on Vaccine Information Statement (VIS)	Vaccine Manf.	Vaccine Lot Number	Site Given ²	Route ³	Signature of Vaccine Administrator	Client Status
Tetanus. diphtheria Td with acellular pertussis Types are: Td Tdap									
Hepatitis B Types are: HepB HepB-HepA									
Measles, Mumps, Rubella Type is: MMR									
Varicella Type is: Var									
Influenza Types are: TIV (Injectable) LAIV (Nasal) (See Back for Additional Spaces)									
Pneumococcal Type is: PPV23									
Hepatitis A Types are: HepA HepB-HepA									
Meningococcal Types are: MCV4 MPSV4									
Human Papillomavirus Type: HPV4									
Zoster Type; Zoster									
Other Other Other Other									

¹ Place an asterisk (*) next to the date the vaccine was given to indicate vaccines administered elsewhere ² Site Code: LA=LT ARM, RA=RT ARM, LL=LT LEG, RL=RT LEG, and Nasal

³ Route Code: IM=intramuscular, SC=subcutaneous, and intranasal

⁴ Client VFC Status: M=Medicaid, U=Uninsured, D=Underinsured, A=American Indian or Alaskan Native, P=Private Insurance,

Vaccine	Date Vaccine & Vaccine Information Statement Given	Type of Vaccine	Date on Vaccine Information Statement (VIS)	Vaccine Manf.	Vaccine Lot Number	Site Given ²	Route ³	Signature of Vaccine Administrator	Client Status ⁴
Influenza									
Types are: TIV (Injectable) LAIV (Nasal)									
Notes:									

Note:

Patients/parents should be informed about the risks and benefits associated with immunizations including those associated with the vaccine-preventable disease. Federal and state guidelines do not require a patient/parent signature to administer vaccines. However, health care providers have the option to obtain a signature. Check with your agency for specific requirements.

I have been given a copy and have read, or have had explained to me, the information contained on the appropriate Vaccine Information Statement (VIS) about the disease(s) and the vaccine(s) which are to be administered today. I have had a chance to ask questions that were answered to my satisfaction. I understand the benefits and risks of the specific vaccine(s) and I ask that the vaccine(s) I have requested be given to me, or to the person named, for whom I am authorized to make this request.

1. SIGNATURE	DATE	Insurance Status	6. SIGNATURE	DATE	Insurance Status
2. SIGNATURE	DATE	Insurance Status	7. SIGNATURE	DATE	Insurance Status
3. SIGNATURE	DATE	Insurance Status	8. SIGNATURE	DATE	Insurance Status
4. SIGNATURE	DATE	Insurance Status	9. SIGNATURE	DATE	Insurance Status
5. SIGNATURE	DATE	Insurance Status	10. SIGNATURE	DATE	Insurance Status



December 18, 2006

Important Vaccine Information Statement (VIS) Facts

VIS now posted on MDCH website

The English language Vaccine Information Statements (VIS) are now posted on our website. We are also in the process of posting the foreign language VIS.

In Michigan, it is important that vaccine recipients, their parents, or their legal representatives be given the Michigan version of the VIS because they include information about the Michigan Care Improvement Registry (MCIR). By state law, parents must be informed about MCIR. Vaccine Information Statements that are obtained from other sources (e.g., from the CDC or IAC websites) do not contain information about MCIR.

www.michigan.gov/immunize

Foreign Languages

The VIS are available in 33 foreign languages. They include information about MCIR. When the foreign language VIS is not the most current version, parents should also be given the current English version. To receive the VIS in a foreign language, call the MDCH Division of Immunization at 517-335-8159.

We are currently in the process of posting the foreign language VIS on the MDCH website. The foreign language VIS will be posted at www.michigan.gov/immunize.

VIS documentation procedures

By noting the version date of the VIS on the patient's vaccine administration record, the provider is indicating that the parent and/or patient received the most current information about the vaccine. To document this, the provider must note in the patient's medical record the date the VIS was given and the version date of the VIS.

VIS Version D	ates (as of 1/	11/07)
VIS	Current Version Date	New Version Dates
HPV	Interim 9-5-06	
Нер В	7-11-01	
DTaP	7-30-01	
Td	6-10-94	
Tdap	Interim 7-12-06	
Hib	12-16-98	
IPV	1-1-00	
MMR	1-15-03	
VAR	Interim 1-10-07	
PCV	9-30-02	
PPV23	7-29-97	
Нер А	3-21-06	
TIV (Flu)	Updated annually	
LAIV (Flu)	Updated annually	
Meningococcal* (MCV4 & MPSV4)	Interim 11-16-06	
Rota (Rotavirus)	Interim 4-12-06	
Zoster (Shingles)	Interim 9-11-06	

VIS are available in these foreign languages

Albanian	Croatian (Serbian)	llokano	Portuguese	Spanish
Arabic	Farsi	ltalian	Punjabi	Tagalog
Armenian	French	Japanese	Romanian	Thai
Bosnian	German	Korean	Russian	Turkish
Burmese	Haitian Creole	Laotian	Samoan	Vietnamese
Cambodian	Hindi	Marshallese	Serbo-Croatian	
Chinese	Hmong	Polish	Somali	

11 Revised 1/11/07

Give the birth dose ...

Hepatitis B vaccine at birth saves lives!

By Deborah L. Wexler, MD, Executive Director, Immunization Action Coalition

On Dec. 23, 2005, CDC issued new recommendations on hepatitis B vaccination that were published in the MMWR. The recommendations strongly support the birth dose of hepatitis B vaccine for every newborn prior to hospital discharge and also recommend the use of standing orders for giving the birth dose. Copies of original maternal hepatitis B lab reports are also recommended (instead of transcribed test results). According to the new recommendations, the birth dose should only be withheld in "rare circumstances," and if doing so, physicians should write an order not to give the dose, and a copy of the mother's original HBsAg-negative lab report must be on the infant's chart. The American Academy of Pediatrics, American Academy of Family Physicians, and American College of Obstetricians and Gynecologists endorse these new recommendations.

The Immunization Action Coalition (IAC) urges all health professionals and hospitals to protect all infants from hepatitis B virus (HBV) infection by administering the first dose of hepatitis B vaccine to every infant at birth and no later than hospital discharge.

Approximately 19,000 women with chronic hepatitis B virus infection give birth in the U.S. each year. Up to 95% of perinatal infections can be prevented by postexposure prophylaxis given within 12 hours of birth. Tragically, many babies are exposed to HBV at birth but do not receive appropriate postexposure prophylaxis.

The primary advantage of giving the first dose at birth is that IT SAVES LIVES.

Why is such a policy necessary? Following are some of the ways infants who are not vaccinated at birth can become infected:

- The pregnant woman is tested and found to be hepatitis B surface antigen (HBsAg) positive, but her status is not communicated to the newborn nursery. The infant receives neither hepatitis B vaccine nor HBIG protection at birth.
- A chronically infected pregnant woman is tested with the wrong test. For example, antibody to hepatitis B surface antigen is sometimes ordered in error instead of HBsAg. This can happen because some laboratories use the improper and confusing abbreviation HBsAb instead of anti-HBs. This misordering of a test is relatively common since the two abbreviations (HBsAg and HBsAb) differ by only one letter. However, when her incorrectly ordered test comes back "negative," the woman may have actually been HBsAg positive and her infant would not receive appropriate postexposure prophylaxis.
- The pregnant woman is HBsAg positive, but her test results are misinterpreted or mistranscribed into her prenatal record or her infant's chart. Her infant does not receive HBIG or hepatitis B vaccine.
- The pregnant woman is not tested for HBsAg ei-

- ther prenatally or in the hospital at the time of delivery. Women in this group have a higher likelihood of being HBsAg-positive (in one study, women who didn't receive prenatal care were 8 times more likely to be HBsAg positive than women who received such care). Her infant does not receive hepatitis B vaccine in the hospital, even though it is recommended within 12 hours of birth for infants whose mothers' test results are unknown.
- The woman is tested in early pregnancy for HBsAg and is found to be negative. She develops HBV infection later in pregnancy, but it is not detected, even though it is recommended by CDC that high-risk women be retested later in pregnancy. Because the infection is not clinically detected by her health care provider, her infant does not receive hepatitis B vaccine or HBIG at birth.
- The mother is HBsAg negative, but the infant is exposed to HBV postnatally from another family member or caregiver. This occurs in twothirds of the cases of childhood transmission.

While there are certain advantages to giving the first dose at a later well-baby visit, these are advantages of administrative convenience. The primary advantage of giving the first dose at birth is that it saves lives.

In 2001 and 2002, IAC surveyed hepatitis coordinators at every state health department as well as at city and county CDC projects to express their views about providing hepatitis B vaccine in the hospital. Their responses contained many examples of children who were unprotected or inadequately protected because health professionals failed to order or misordered the hepatitis B blood test or misinterpreted, mistranscribed, or miscommunicated the test results of the children's mothers.

These state coordinators' reports tell us that no matter how well healthcare providers think they are doing with HBsAg screening of all pregnant women, serious mistakes continue to occur; children are unnecessarily being exposed without the benefit of postexposure prophylaxis, and at least

To obtain the CDC recommendations (12/23/05) for hepatitis B immunization of infants, children, and adolescents, go to: www.cdc.gov/mmwr/pdf/rr/rr54l6.pdf.

For more information on the importance of giving the birth dose, and results from IAC's survey of state hepatitis B coordinators, go to: www.immunize.org/birthdose.

one baby has died. In order to overcome these failures, all 50 state hepatitis B coordinators overwhelmingly endorse providing a birth dose.

To maximally protect every newborn, ACIP recommends we vaccinate *all* infants (regardless of the mother's HBsAg status) prior to hospital discharge with Engerix-B® or Recombivax HB®. Providers who wish to complete the series using hepatitis B-containing combination vaccines (Comvax®, Pediarix®), may do so by giving three additional doses. Giving a total of four doses of hepatitis B vaccine to infants is acceptable to CDC, AAP, AAFP, and these vaccine doses are covered under the Vaccines for Children (VFC) program.

All 50 state hepatitis B coordinators overwhelmingly endorse providing a birth dose.

Hepatitis B vaccine is a highly effective vaccine. Studies have shown that infants of the most highly infectious mothers (women who are both HBsAg and HBeAg positive) who receive postexposure prophylaxis with hepatitis B vaccine alone (without HBIG) at birth are protected in up to 95% of cases, essentially the same level of protection afforded by administering hepatitis B vaccine in addition to HBIG. Even higher rates of protection with postexposure prophylaxis have been demonstrated in infants born to less infectious mothers (those who are HBsAg positive and HBeAg negative).

Please read the hepatitis coordinators' survey results (see the web address box above), including descriptions of their experiences with failures of the current system—failures that largely will be prevented by administering hepatitis B vaccine to infants before they go home from the hospital.

Your support for providing a birth dose of hepatitis B vaccine to infants while still in the hospital will protect and save lives that are now being put at risk. ◆

www.immunize.org/catg.d/p2125.pdf • Item #P2125 (5/06)

Hepatitis B Vaccine and Hepatitis B Immune Globulin Administration for Infants

- 1		*: 0000 :
Maternal Status	Intants greater than or equal to 2000 g	Intants less than 2000 g
Hepatitis B Surface Antigen (HBsAg) positive	Give single-antigen hepatitis B (hepB) vaccine and hepatitis B immune globulin (HBIG) within 12 hours of birth.	Give single-antigen hepB vaccine and HBIG within 12 hours of birth.
-	Complete the hepB vaccine series with single-antigen doses at 1-2 and 6 months of age or hepB-containing	Do not count the hepB birth dose as the first dose. Initiate the full hepB vaccine series with single-antigen doses at 1,
	2, 4, and 12-15 months of age depending on the	vaccines given at 2, 4, and 6 months of age, or 2, 4, and
	combination product used. (Combination vaccines cannot be given before 6 weeks of age.)	12-15 months of age depending on the combination product used. (Combination vaccines cannot be given before 6 weeks of age.)
	Test for hepatitis B surface antibody (anti-HBs) and HBsAg at 9-18 months of age (3 months after the completion of the hepB vaccine series).	Test for anti-HBs and HBsAg at 9-18 months of age (3 months after the completion of the hepB vaccine series).
	If the infant is HBsAq and anti-HBs negative repeat the 3	
	dose hepB vaccine series and retest 1-2 months after the completion of the second vaccine series.	If infant is HBsAg and anti-HBs negative, repeat the 3 dose hepB vaccine series and retest 1-2 months after the
	If infant is HBsAg-positive, refer to a specialist.	completion of the second vaccine series.
LBc As status	Toot mothor CTAT for UBcAs	That mother STAT for UBSA
n bs Ag status unknown	rest mother STAL for HDSAg.	rest mother STAT for HDSAg.
	Give single-antigen hepB vaccine within 12 hours of birth and HBIG within 7 days if mom's status remains unknown or sooner if found to be HBsAg-positive.	Give single-antigen hepB vaccine and HBIG within 12 hours of birth if mom's status remains unknown or if found to be HBsAg-positive.
	Follow the recommended vaccination schedule.	Follow the recommended vaccination schedule.
HBsAg-negative	Give single-antigen hepB vaccine at birth or prior to hospital discharge.	Give single-antigen hepB vaccine to medically stable infants at 30 days of chronologic age or at hospital discharge if before 30 days of chronologic age
	Follow the recommended vaccination schedule.	
	Anti-HRs and HRs An testing is not recommended	Follow the recommended vaccination schedule.
		Anti-HBs and HBsAg testing is not recommended.

^{*} All doses of hepB vaccine and HBIG must be entered into the Michigan Care Improvement Registry (MCIR). This may be done by entering the data directly into the MCIR or on the Electronic Birth Certificate (EBC). It is important that all providers who see the baby in a neonatal intensive care unit (NICU) or in an office enter the dose information into MCIR so that a follow-up provider knows when to give the next dose.

[•] Adapted from: Saari TN and the Committee on Infectious Diseases, Immunization of Preterm and Low Birth Weight Infants. Pediatrics 2003; 112:193-198.



Recommended Dosages of Hepatitis B Vaccine and Hepatitis B Immune Globulin

Henatitis B	Engerix-B® (GlaxoS	(GlaxoSmithKline)	Recombivax HB® (Merck)	(Merck)
Vaccine Recipient	Pediatric Formulation Blue Cap	Adult Formulation	Pediatric/Adolescent Formulation Yellow Cap	Adult Formulation
	10mcg (0.5mL) (or in prefilled syringes)	Orange Cap 20mcg (1mL)	5mcg (0.5m <u>L)</u>	Green Cap 10mcg (1mL)
Newborns born to HBsAg (+)	$10 \text{mcg} (0.5 \text{mL})^{1} \& (0.5 \text{mL})$		$5 \text{mcg} (0.5 \text{mL})^{1} & (0.5 \text{mL})$	
momers.	HBIG within 12 hours of birth		HBIG within 12 hours of birth	
Newborns born to mothers	$10 \text{mcg} (0.5 \text{mL})^{1}$		$5 mcg (0.5 mL)^{1}$	
whose HBsAg status is	within 12 hours of birth; (0.5mL)		within 12 hours of birth; (0.5mL)	
unknown*	HBIG should also be given		HBIG should also be given	
	within 7 days if mom's status		within 7 days if mom's status	
	remains unknown or sooner if		remains unknown or sooner if	
	found to be HBsAg (+)		found to be HBsAg (+)	
Newborns born to HBsAg (-)				
mothers* and children up to 10	$10 \text{mcg} (0.5 \text{mL})^{1/3}$		$5 mcg (0.5 mL)^{1/2}$	
years of age				
11-19 years ⁴	10mcg (0.5mL)		5mcg (0.5mL)	
20 + years ⁴		20mcg (1mL)		10mcg (1mL)
Dialysis patients		40mcg (2mL) ⁵		Blue Cap
				40mcg (1mL) ⁶

^{*}For newborns weighing less than 2000 g, see (Hepatitis B Vaccine and Hepatitis B Immune Globulin Administration for Infants pg 13 of the Perinatal Hepatitis B Manual)

^{&#}x27;Merck's Comvax® (hepatitis B and Hib) is a combination vaccine that may be used as an alternative to single antigens for administration to any child 6 weeks of age and older at 2, 4 and 12-15 Hepatitis B vaccine is strongly recommended at birth. This birth dose MUST be a single antigen vaccine. A 4-dose hepatitis B series is approved in conjunction with Pediarix® or Comvax®.

months of age when neither antigen is contraindicated. This combination vaccine is NOT to be given at birth.

combination vaccine is NOT to be given at birth. It may be given to any child between the ages of 6 weeks to 7 years of age for whom none of the antigens are contraindicated, and only as a *GlaxoSmithKline's Pediarix® (DTaP, hepatitis B and IPV) is a combination vaccine that may be used as an alternative to single antigens for administration at 2, 4 and 6 months of age. This primary series. (The primary series is considered the first three doses of DTaP and IPV vaccines.)

^{*}HBIG (hepatitis B immune globulin) All susceptible contacts of an HBsAg (+) person, should receive a (0.06 mL/kg) dose of HBIG, within 7 days of a blood exposure, or within 14 days of a sexual exposure, along with the hepatitis B vaccine series.

Engerix-B® dialysis formulation is approved for adult hemodialysis patients by using 2 x 20mcg/1mL in one or two injections at 0, 1, 2 and 6 months.

^{&#}x27;Recombivax HB® dialysis formulation is approved for pre-dialysis and dialysis patients in a three dose series of 40mcg/1mL at 0, 1, and 6 months.

be administered 4-6 months after the first dose. If the 2-dose regimen is used, documentation must indicate that the adolescent received 2 adult 10mcg (1ml) doses of the Merck brand. If a child Merck's 2-dose (adolescent) hepatitis B vaccine series (using the adult formulation of Recombivax HB® 10mcg, 1 ml) is approved only for adolescents 11-15 years of age. The second dose should starts the hepatitis B series prior to age 11, starts the hepatitis B series between the ages of 11 and 15 with a hepatitis B vaccine other than the adult formulation of the Merck product, or completes the series after age 15, a 3-dose series should be administered. This specific use of vaccine is not included in the VFC program.

GlaxoSmithKline's Twinrix® (hepatitis A and hepatitis B) is a combination vaccine that may be used as an alternative to single antigens for persons 18 years of age and older. It is recommended for administration at intervals of 0, 1 & 6 months to any adult for whom neither antigen is contraindicated.

For specific prescribing information, precautions, contraindications, and specific dialysis formulations, refer to product inserts.

HEPATITIS B VACCINE

WHAT YOU NEED TO KNOW

1 Why get vaccinated?

Hepatitis B is a serious disease.

The hepatitis B virus (HBV) can cause short-term (acute) illness that leads to:

- · loss of appetite
- diarrhea and vomiting
- tiredness
- jaundice (yellow skin or eyes)
- pain in muscles, joints, and stomach

It can also cause long-term (chronic) illness that leads to:

- liver damage (cirrhosis)
- · liver cancer
- death

About 1.25 million people in the U.S. have chronic HBV infection.

Each year it is estimated that:

- 80,000 people, mostly young adults, get infected with HBV
- More than 11,000 people have to stay in the hospital because of hepatitis B
- 4,000 to 5,000 people die from chronic hepatitis B

Hepatitis B vaccine can prevent hepatitis B. It is the first anti-cancer vaccine because it can prevent a form of liver cancer.

2 How is hepatitis B virus spread?

Hepatitis B virus is spread through contact with the blood and body fluids of an infected person. A person can get infected in several ways, such as:

- by having unprotected sex with an infected person
- by sharing needles when injecting illegal drugs
- · by being stuck with a used needle on the job
- during birth when the virus passes from an infected mother to her baby

About 1/3 of people who are infected with hepatitis B in the United States don't know how they got it.

Hepatitis B

7/11/2001

Who should get hepatitis B vaccine and when?

- 1) Everyone 18 years of age and younger
- 2) Adults over 18 who are at risk

Adults at risk for HBV infection include:

- people who have more than one sex partner in 6 months
- men who have sex with other men
- sex contacts of infected people
- people who inject illegal drugs
- health care and public safety workers who might be exposed to infected blood or body fluids
- household contacts of persons with chronic HBV infection
- hemodialysis patients

If you are not sure whether you are at risk, ask your doctor or nurse.

✓ People should get 3 doses of hepatitis B vaccine according to the following schedule. If you miss a dose or get behind schedule, get the next dose as soon as you can. There is no need to start over.

	4141 - D		WHO?	
Va	patitis B ccination hedule	Infant whose mother is infected with HBV	Infant whose mother is <i>not</i> infected with HBV	Older child, adolescent, or adult
w	First Dose	Within 12 hours of birth	Birth - 2 months of age	Any time
H E N	Second Dose	1 -2 months of age	1 - 4 months of age (at least 1 month after first dose)	1 - 2 months after first dose
?	Third Dose	6 months of age	6 - 18 months of age	4 - 6 months after first dose

- The second dose must be given at least 1 month after the first dose.
- The third dose must be given at least 2 months after the second dose and at least 4 months after the first.
- The third dose should *not* be given to infants under 6 months of age, because this could reduce long-term protection.

Adolescents 11 to 15 years of age may need only two doses of hepatitis B vaccine, separated by 4-6 months. Ask your health care provider for details.

Hepatitis B vaccine may be given at the same time as other vaccines.

4

Some people should not get hepatitis B vaccine or should wait

People should not get hepatitis B vaccine if they have ever had a life-threatening allergic reaction to baker's yeast (the kind used for making bread) or to a previous dose of hepatitis B vaccine.

People who are moderately or severely ill at the time the shot is scheduled should usually wait until they recover before getting hepatitis B vaccine.



Ask your doctor or nurse for more information.

5

What are the risks from hepatitis B vaccine?

A vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of hepatitis B vaccine causing serious harm, or death, is extremely small.

Getting hepatitis B vaccine is much safer than getting hepatitis B disease.

Most people who get hepatitis B vaccine do not have any problems with it.

Mild problems

- soreness where the shot was given, lasting a day or two (up to 1 out of 11 children and adolescents, and about 1 out of 4 adults)
- mild to moderate fever (up to 1 out of 14 children and adolescents and 1 out of 100 adults)

Severe problems

• serious allergic reaction (very rare)



What if there is a moderate or severe reaction?

What should I look for?

Any unusual condition, such as a serious allergic reaction, high fever or unusual behavior. Serious allergic DCH-0450

reactions are extremely rare with any vaccine. If one were to occur, it would be within a few minutes to a few hours after the shot. Signs can include difficulty breathing, hoarseness or wheezing, hives, paleness, weakness, a fast heart beat or dizziness.

What should I do?

- Call a doctor, or get the person to a doctor right away.
- Tell your doctor what happened, the date and time it happened, and when the vaccination was given.
- Ask your doctor, nurse, or health department to report the reaction by filing a Vaccine Adverse Event Reporting System (VAERS) form.

Or you can file this report through the VAERS web site at www.vaers.org, or by calling 1-800-822-7967.

VAERS does not provide medical advice

7

The National Vaccine Injury Compensation Program

In the rare event that you or your child has a serious reaction to a vaccine, a federal program has been created to help you pay for the care of those who have been harmed.

For details about the National Vaccine Injury Compensation Program, call 1-800-338-2382 or visit the program's website at www.hrsa.gov/osp/vicp

$\overline{8}$

How can I learn more?

- Ask your doctor or nurse. They can give you the vaccine package insert or suggest other sources of information.
- Call your local or state health department's immunization program. 1-888-767-4687
- Contact the Centers for Disease Control and Prevention (CDC):
 - -Call 1-800-232-4636 (1-800-CDC-INFO) or 1-888-443-7232
 - -Visit the National Immunization Program's website at www.cdc.gov/nip or CDC's Division of Viral Hepatitis website at www.cdc.gov/hepatitis





U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Disease Control and Prevention National Immunization Program

Vaccine Information Statement

Hepatitis B (7/11/01)

42 U.S.C. § 300aa-26

AUTH: P.H.S., Act 42, Sect. 2126.

To allow medical care provider(s) accurate immunization status information, an immunization assessment, and a recommended schedule for future immunizations, information will be sent to the Michigan Care Improvement Registry. Individuals have the right to request that their medical care provider not forward immunization information to the Registry.

Important Vaccine Information Statement (VIS) Facts

VIS now posted on MDCH website

The English language Vaccine Information Statements (VIS) are now posted on our website. We are also in the process of posting the foreign language VIS.

In Michigan, it is important that vaccine recipients, their parents, or their legal representatives be given the Michigan version of the VIS because they include information about the Michigan Care Improvement Registry (MCIR). By state law, parents must be informed about MCIR. Vaccine Information Statements that are obtained from other sources (e.g., from the CDC or IAC websites) do not contain information about MCIR.

www.michigan.gov/immunize

Foreign Languages

The VIS are available in 33 foreign languages. They include information about MCIR. When the foreign language VIS is not the most current version, parents should also be given the current English version. To receive the VIS in a foreign language, call the MDCH Division of Immunization at 517-335-8159.

We are currently in the process of posting the foreign language VIS on the MDCH website. The foreign language VIS will be posted at www.michigan.gov/immunize.

VIS documentation procedures

By noting the version date of the VIS on the patient's vaccine administration record, the provider is indicating that the parent and/or patient received the most current information about the vaccine. To document this, the provider must note in the patient's medical record the date the VIS was given and the version date of the VIS.

VIS Version D)ates (as of 1/2	11/07)
VIS	Current Version Date	New Version Dates
HPV	Interim 9-5-06	
Нер В	7-11-01	
DTaP	7-30-01	
Td	6-10-94	
Tdap	Interim 7-12-06	
Hib	12-16-98	
IPV	1-1-00	
MMR	1-15-03	
VAR	Interim 1-10-07	
PCV	9-30-02	
PPV23	7-29-97	
Нер А	3-21-06	
TIV (Flu)	Updated annually	
LAIV (Flu)	Updated annually	
Meningococcal* (MCV4 & MPSV4)	Interim 11-16-06	
Rota (Rotavirus)	Interim 4-12-06	
Zoster (Shingles)	Interim 9-11-06	

VIS are available in these foreign languages

Albanian	Croatian (Serbian)	llokano	Portuguese	Spanish
Arabic	Farsi	ltalian	Punjabi	Tagalog
Armenian	French	Japanese	Romanian	Thai
Bosnian	German	Korean	Russian	Turkish
Burmese	Haitian Creole	Laotian	Samoan	Vietnamese
Cambodian	Hindi	Marshallese	Serbo-Croatian	
Chinese	Hmong	Polish	Somali	

16 Revised 1/11/07

Vaccine Administration Record for Children and Teens

 Patient Name:
 Any Child

 Date of Birth:
 11/30/2002

Clinic Name/Address

Guide for using this form...

MCIR ID#

Vaccine	Date Vaccine 4 Vaccine Waccine Information Statement Given	Type of Vaccine	Date on Vaccine Information Statement (VIS)	Vaccine Manf.	Vaccine Lot Number	Site Given ²	Route ³	Signature of Vaccine Administrator	Client VFC Status ⁴
Diphtheria,	02/05/03	DTap-HepB-IPV	7/30/01	GSK	635A	RT	IМ	Sally Woods MA	М
Tetanus, Pertussis	04/05/03	DTap-НерВ-IPV	7/30/01	SSK	712A2	RT	IМ	Sally Woods MA	М
Types are: DTaP DT	06/05/03	DTap-НерВ-IPV	7/30/01	GSR	712A2	RT	IМ	Sally Woods MA	М
DTaP-Hib DTaP-HepB-IPV Tdap Td	[*]	Indicates v elsewhere.	accine g	iven	Same sh Stateme			Vaccine Information dates	ion P
Haemophilus influenzae type b	02/05/03	Нів	12/16/98	AVP	UA7443A	LT	IM	Sally Woods MA	М
Types are:	04/05/03	Hi6	12/16/98	AVP	V2/44AA	LT	IM	Sally Woods MA	M
Hib Hib-HepB DTaP-Hib	06/05/03	Hib .	12/16/98	AVP	UA744AA	$\frac{\mathcal{L}T}{\mathcal{L}T}$	IM	Sally Woods MA	M
Hepatitis B	<u> </u>		12/10/50	J. r. p	- Optivipie	+			JIL
Types are:	12/02/02*	Нер В	7/11/01	O COOK	(25.42	Given	at	Anywhere Hospital	21
HepB Hib-HepB	02/05/03	DTap-HepB-IPV	7/11/01	GSK	635,82	RT	IM TOA	Sally Woods MA	M
DTaP-HepB-IPV	04/05/03	DTap-HepB-IPV DTap-HepB-IPV	7/11/01	GSK	712A2	RT	IM IM	Sally Woods MA	M
	06/03/03	Ф1ар-лерь-14V	7/11/01	GSK /	712A2	RT	$I\mathcal{M}$	Sally Woods MA	М
Hepatitis A Type is: HepA									
Polio	02/05/03	DTap-HepB-IPV	1/01/00	GSK	635A2	RT	IМ	Sally Woods MA	м
Types are:	04/05/03	DTap-HepB-IPV	1/01/00	GSK	712A2	RT	IМ	Sally Woods MA	М
IPV DTaP-HepB-IPV	06/05/03	DTap-HepB-IPV	1/01/00	GSK.	712A2	RT	IМ	Sally Woods MA	М
Measles, Mumps, Rubella Types are : MMR MMRV	12/20/03	MMR	1/15/03	MRK	0857М	L.A	SC	Linda Miller MA	М
<u>V</u> aricella	Disease date							N. Carlotte	
Types are: Var MMRV	11/15/03		Росит	nents d	isease history				
	02/05/03	PCV 7	7,,,,,,,		1.402-017	RT	IМ	Sally Woods MA	М
Pneumococcal conjugate	04/05/03	PCV 7	9/30/02	WYE	489-835	RT	IM	Sally Woods MA	M
Type is: PCV7	06/05/03	PCV 7	9/30/02	WYE	489-835	$\mathcal{R}\mathcal{T}$	IМ	Sally Woods MA	М
Type is. FCV7	03/05/04	PCV 7	9/30/02	WYE	501-245	LT	IМ	Sally Woods MA	М
Rotavirus Type is: Rota									
Influenza Types are: TIV (Injectable) LAIV (Intranasal) (More space on the reverse side.)					How to complete — Single Vacci		 ministra	 tion record for:	
Meningococcal Types are: MCV4 MPSV4					 Combination Vaccines tha History of C 	t are giv	en else		
Human Papillomavirus Type is: HPV4						HERBIELDER GENERAL			

Place an asterisk (*) next to the date the vaccine was given to indicate vaccines administered elsewhere.
 Site Code: LA=LT ARM, RA=RT ARM, LL=LT LEG, RL=RT LEG
 Route Code: IM= intramuscular, SC=subcutaneous, IN=intranasal, PO=oral
 Client Status: M=Medicaid, U=Uninsured, D=Underinsured, P=Private Insurance, A=American Indian or Alaskan Native, V=MIVRP, L=Other Public Purchase

Vaccine Ad Patient Nam		n Record fo	r Children	and Te	ens	Clinic Name/Add	ress		
Date of Birth	ı: <u> </u>								
MCIR ID#									
	Dete								

WOII CIBII									
Vaccine	Date Vaccine & Vaccine Information Statement Given	Type of Vaccine	Date on Vaccine Information Statement (VIS)	Vaccine Manf.	Vaccine Lot Number	Site Given ²	Route ³	Signature of Vaccine Administrator	Client VFC Status
Diphtheria, Tetanus, Pertussis Types are: DT aP DT aP-Hib DT aP-HepB-IPV Tdap									
Haemophilus influenzae type b Types are: Hib Hib-HepB DTaP-Hib									
Hepatitis B Types are: HepB Hib-HepB DTaP-HepB-IPV									
Hepatitis A Type is: HepA									
Polio Types are: IPV DTaP-HepB-IPV									
Measles, Mumps, Rubella Types are : MMR MMRV									
Varicella Types are: Var MMRV									
Pneumococcal conjugate Type is: PCV7									
Rotavirus Type is: Rota									
Influenza Types are: TIV (Injectable) LAIV (Intranasal) (More space on the reverse side.)									
Meningococcal Types are: MCV4 MPSV4									
Human Papillomavirus Type is: HPV4									

Place an asterisk (*) next to the date the vaccine was given to indicate vaccines administered elsewhere.

Site Code: LA=Left Arm, RA=Right Arm, LL=Left Leg, RL= Right Leg

Route Code: IM= Intramuscular, SC=Subcutaneous, IN= Intranasal, PO=Oral
Client Status: M=Medicaid, U=Uninsured, D=Underinsured, P=Private Insurance, A=American Indian or Alaskan Native, V=MIVRP, L=Other Public Purchase

December 8, 2

B	5 . (5)		
Patient Name:	Date of Birth:	MCIR ID#	
i alicili Nailie.	Date of Diffi.	IVICII I ID#	

Vaccine	Date Vaccine & Vaccine Information Statement Given	Type of Vaccine	Date on Vaccine Information Statement (VIS)	Vaccine Manf.	Vaccine Lot Number	Site Given ²	Route ³	Signature of Vaccine Administrator	Client VFC Status
Influenza Types are:									
TIV									
LAIV									
Other									
Other									
Other									
Other									

Note:

Patients/parents should be informed about the risks and benefits associated with immunizations including those associated with the vaccine-preventable disease. Federal and state guidelines do not require a parent/patient signature to administer vaccines. However, health care providers have the option to obtain a signature. Check with your agency for specific requirements.

I have been given a copy and have read, or have had explained to me, the information contained on the appropriate Vaccine Information Statement (VIS) about the disease(s) and the vaccine(s) which are to be administered today. I have had a chance to ask questions that were answered to my satisfaction. I understand the benefits and risks of the specific vaccine(s) and I ask that the vaccine(s) I have requested be given to me, or to the person named, for whom I am authorized to make this request.

1. SIGNATURE	DATE	Insurance Status	8. SIGNATURE	DATE	Insurance Status
2. SIGNATURE	DATE	Insurance Status	9. SIGNATURE	DATE	Insurance Status
3. SIGNATURE	DATE	Insurance Status	10. SIGNATURE	DATE	Insurance Status
4. SIGNATURE	DATE	Insurance Status	11. SIGNATURE	DATE	Insurance Status
5. SIGNATURE	DATE	Insurance Status	12. SIGNATURE	DATE	Insurance Status
6. SIGNATURE	DATE	Insurance Status	13. SIGNATURE	DATE	Insurance Status
7. SIGNATURE	DATE	Insurance Status	14. SIGNATURE	DATE	Insurance Status





Hepatitis B Perinatal Case Report - Infant/Contact

Michigan Department of Community Health (MDCH)

Please complete this form each time a dose of hepatitis B vaccine and/or hepatitis B immune globulin (HBIG) is administered to an infant whose mother has tested hepatitis B surface antigen (HBsAg) positive or when given to her household or sexual contacts. Mail this form to MDCH, Immunization Division, P.O. Box 30195, Lansing, MI 48909, fax to 517-335-9855, or call the Perinatal Hepatitis B Prevention staff at 517-335-8122 or 800-964-4487. In southeast Michigan, mail to MDCH, Detroit Regional Office, 3056 West Grand Boulevard, Suite 3-150, Detroit, MI 48202, fax to 313-456-4427 or call 313-456-4431 or 313-456-4432. Also, please make sure to update the infant/contact's Michigan Care Improvement Registry (MCIR) record

the infant/co	ontact's Michiga	n Care Improveme	ent Registry (MCII	R) re	cord.				
PROVIDE	R								
Hospital or P	rovider Name						County		
Address									
City				Zip	Code		Telephone No.		
HBsAg PO	SITIVE MOTHI	ER							
Mother's Na	me			DO	В		Grav		Para
Address									
City				Zip	Code		County of Residence		
Social Securi	ty No.		Telephone No.				Emergency/Work No	-	
HBsAg-posit	ive Test Result Date	;			Mom's Medica	l Recor	d No. (if infant)		
INFANT O	R HOUSEHOLI	D/SEXUAL CONT	ACT						
Name						DOB		Sex	☐ Male ☐ Female
Race/Ethnicit	☐ Alaska ☐ Other			Pacifi	c Islander 🗆 E	Black	□ Caucasian	□ Hispa	nic Unknown
Birth Weight	(If infant)				Medical Record	l No (I	f infant)		
VACCINE	LAB RESULTS	OF INFANT OR	CONTACT						
Vaccine	Date Given	Lot #	Manufacturer	•	Dosage		Lab Results		Date of Test
HBIG						HBsA	v g		
Hep B #1						Anti-l	HBs		
Hep B #2						Other			
Hep B #3									
FOLLOW	-UP CARE PR	OVIDER OF IN	FANT OR CONT	TAC'	T (If differer	nt fro	m above)		
Facility Name	e				Provider's Nam	ne			
Address					City			Zip Code	
Telephone N	0.				County				
	on completing					l	ohone		

Patients may NOT be charged for cost of vaccines provided through project grant funds whether administered in public clinics or by private physicians. Vaccine may NOT BE DENIED in public clinics for failure to pay an administration fee or to make a donation to the provider.

19

DCH-0973 AUTHORITY: PA 368 of 1978




Submission of the Electronic Birth Certificate (EBC) Hospital Worksheet

BEST PRACTICE

Baby is born.

OTHER

Baby is born.



A hospital worksheet is completed and the hepB vaccine and/or HBIG administration date is noted. This worksheet information will be used to complete the Electronic Birth Certificate (EBC) record.

Hospital staff submits the completed EBC record to the Michigan Department of Community Health (MDCH). Baby gets birth dose of hepB vaccine and/or HBIG.

A hospital worksheet is completed but the hepB vaccine and/or HBIG administration date is not noted.

Hospital staff needs to get the hepB vaccine and/or the HBIG administration date from the baby's chart and record the date on the worksheet so it can be entered on the EBC record prior to submitting to MDCH.

Hospital staff submits the completed EBC record to MDCH *If an EBC record is submitted to MDCH prior to entering the hepB vaccine and/or HBIG administration date, the administration can only be added to the Michigan Care Improvement Registry (MCIR) by directly entering it into the MCIR. (Once the web link is available, staff should get the administration date from the baby's chart and enter information into the MCIR).

Hospital staff needs to enter the hepB vaccine and/or HBIG administration date into the MCIR via the web. Staff should contact their regional MCIR coordinators for MCIR passwords, ID's and appropriate procedural guidelines.

1. CHILD - NAM	ME	(FIF	RST)		(MIDDLE)		(LAST)		(SUFFIX)
2. SEX	3a. PLUF (Speci	RALITY - Single, Twin,Triple (V)	rt, etc. 3t	b. IF NOT Second	SINGLE BIRTH - First d, Third, etc. (Specify)	4a. DAT	EOF BIRTH (Movet), Day, Yea	7	4b. TIMÉ OF BIRTH
5a, HOSPITAL	NAME (If not hospite	al, give Street and Number)		5b.	CITY, VILLAGE, OR TOW	NSHIP OF	BIRTH	5c. COU	UNTY OF BIRTH
=				- 1					
6. CERTIFIER'S	S NAME & TITLE	(print or type)	74	a ATTENI	DANT'S NAME & TITLE IF	OTHER TH	AN CERTIFIER	_	ENDENT AT BIRTH
7c. MAILING AL	DDRESS OF ATTE	ENDANT (Street No., City or	r Village, State, Zip	p)			- Su		JURSE MIDWIF
8a. MOTHER'S	NAME (First, Middle	o, Last)		ER'S FUL	L NAME BEFORE FIRST	MARRIED	8c. SOCIAL SECURITY N	UMBER 8d	STATE OF BIRTH - NAME COUNTRY IF NOT USA
Se. DATE OF B (Month, Day,		8f. RESIDENCE - CITY (Check one box and sp INSIDE CITY OR VILL TWP, OF	ecily)	TOWNS	HIP 8g.	COUNTY	8h. STATE		8i. MOTHER MARRIED BIRTH OR CONCEI (Yes or Mo)
9a. FATHER'S	NAME (First Miodio I				96. SOCIAL SECURITY N	UMBER	9c. STATE OF BIRTH - NAM IF NOT USA	ME COUNTRY	9d. DATE OF BIRTH (Month, Day, Year)
9e, FATHER'S	MAIL ING ADDRES		No. City or Village	n State To			10s. PATERNITY OFFEREI	1 Tion	PATERNITY ACKNOWLE
	MAILING ADDRES	SS IF DIFFERENT (Street							
	MAILING ADDRES	SS IF DIFFERENT (Street		m,	ay		YES NO		YES NO
11. HISPANIC	12 ANCESTRY-	CONFIDE Mexican, Puerto Rican,	ENTIAL IN	FORM	IATION FOR CON	MUNIT	Y HEALTH USE O		YES NO
	12. ANCESTRY - South America	CONFIDE	ENTIAL IN	FORM	NATION FOR COM	MUNIT	Y HEALTH USE O	NLY 14. EDUCAT (Specify only	YES NO
11. HISPANIC ORIGIN	12. ANCESTRY - South America	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispa	ENTIAL IN	FORM	IATION FOR CON 3. RACE - American Indiar nationality, ic., Chineso,	MUNIT	Y HEALTH USE O	NLY 14. EDUCAT (Specify only	YES NO
11. HISPANIC ORIGIN (Yes or No)	12. ANCESTRY - South America Arab, English,	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispe, French, Finnish, etc. (a)	ENTIAL IN Cuben, Central snic, Afro-Americ pecify below)	FORM	IATION FOR CON 3. RACE - American Indiar nationality, ic., Chineso,	IMUNIT , Black, Wh Filipino, As	Y HEALTH USE O ite etc. If Asian, give ian Indian, etc.	NLY 14. EDUCAT (Specify only	YES NO
11. HISPANIC ORIGIN (Yes or No) 15. EXPECTED SERVICES	12. ANCESTRY- South America Arab, English,	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispe French, Finnish, etc. (sp rMENT FOR MEDICAL edicakt, etc.)	ENTIAL IN Cuben, Central snic, Afro-Americ pecify below)	FORM l or 1: can,	SATION FOR COM 3. RACE - American Indian nationality, ic., Chinese, (specify below) AlLING ADDRESS (Street M.	IMUNIT , Black, Wh Filipino, As	Y HEALTH USE O ite etc. If Asian, give ian Indian, etc.	NLY 14. EDUCAT (Specify only Elementary)S	TION highest grade completed) secondary (0-12) College (1-4)
11. HISPANIC ORIGIN (Yes or No) 15. EXPECTED SERVICES 17a. MEDICAL MOTHER 21. (Do no	12. ANCESTRY - South America Arab, English, D SOURCE OF PAN (Private Insurance, Market Cord Number LIVE BIRTHS of include this child)	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispa, French, Finnish, etc. (sy YMENT FOR MEDICAL edicate, etc.) R OF 17b. MEDICAL CHILD 21c. DATE OF BIRTH (Mc	ENTIAL IN Cuben, Central anic, Afro-Americ pocify below) 16. MOTH	HER'S MA	ARACE - American Indian nationality, ie., Chinese, (specify below) AlLING ADDRESS (Street M. 18. PENDING ADDRESS)	MUNIT, Black, White Filipino, Assembler, City or	Y HEALTH USE O ite etc. If Asian, give ian Indian, etc. Villege, Stafe, Zip)	NLY 14. EDUCAT (Specify only Elementary)'S	TION y highest grade completed) secondary (0-12) College (1-4) TAL 20. TOTAL PRENAT VISITS
11. HISPANIC ORIGIN (Yes or No) 15. EXPECTED SERVICES. 17a. MEDICAL MOTHER 21. (Do no) 21a. NOW LIVIN	12. ANCESTRY - South America Arab, English, SOURCE OF PAN (Private Insurance, Management) RECORD NUMBE LIVE BIRTHS of include this child) NG 21b. NOW E Number	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispa, French, Finnish, etc. (sy YMENT FOR MEDICAL edicate, etc.) R OF 17b. MEDICAL CHILD 21c. DATE OF BIRTH (Mc	ENTIAL IN Cuben, Central anic, Afro-Americ pocify below) 16. MOTH	FORM or 1: ican, 1: HER'S MA WBER OF 21d, O (Spontar after con Nun	ARTION FOR CON 3. RACE - American Indian nationality, ie., Chinese, (specify below) AlLING ADDRESS (Street M. 18. PENDING ADOPTIC YES NO	MUNIT, Black, White Filipino, Assembler, City or	Y HEALTH USE O ite etc. If Asian, give ian Indian, etc. Villege, State, Zip) 19. MONTH OF PREGNA CARE BEGAN	NLY 14. EDUCAT (Specify only Elementary)'S NCY PRENAT	TAL 20. TOTAL PRENAT
11. HISPANIC ORIGIN (Yes or No) 15. EXPECTED SERVICES 17a. MEDICAL MOTHER 21. (Do no) 21a. NOW LIVIN Number None	12. ANCESTRY - South America Arab, English, Engl	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispa, French, Finnish, etc. (sy YMENT FOR MEDICAL edicate, etc.) R OF 17b. MEDICAL CHILD 21c. DATE OF BIRTH (Mc	ENTIAL IN Cuben, Central anic, Afro-Americ pocify below) 16. MOTH	HER'S MA WBER OF 21d. O (Sporita after cor	ARACE - American Indian nationality, ic., Chinese, (specify below) AlLING ADDRESS (Sweet M. 18. PENDING ADDRESS NO THER TERMINATIONS needs and induced at any time needslon) Ther	Black, Wh Filipino, As	Y HEALTH USE O ite etc. If Asian, give ian Indian, etc. Villege, State, Zip) 19. MONTH OF PREGNA CARE BEGAN	NLY 14. EDUCAT (Specify only Elementary)'S NNCY PRENAT HEPAT DATE I	TION y highest grade completed) secondary (0-12) College (1-4) TAL 20. TOTAL PRENAT VISITS TITIS B YES NO HEPATITIS B GIVEN
11. HISPANIC ORIGIN (Yes or No.) 15. EXPECTED SERVICES. 17a. MEDICAL MOTHER 21a. NOW LIVIN Number	12. ANCESTRY - South America Arab, English, Engl	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispe, French, Finnish, etc. (sy YMENT FOR MEDICAL edicakt, etc.) R OF 17b. MEDICAL CHILD 21c. DATE OF BIRTH (MK	ENTIAL IN Cuben, Central anic, Afro-Americ pacity setow) 16. MOTH RECORD NUM LAST LIVE a, Year) 22b, INFANT	HER'S MA MBER OF 21d. O (Sporitar after cor Num Non	ARACE - American Indian nationality, ic., Chinese, (specify below) AlLING ADDRESS (Sweet M. 18. PENDING ADDRESS NO THER TERMINATIONS needs and induced at any time needslon) Ther	MUNIT Black, Wr Filipino, As smbar, City or N 21e. DA TE	Y HEALTH USE O ite etc. If Asian, give ian Indian, etc. Village, Stafe, Zip) 19. MONTH OF PREGNA CARE BEGAN TE OF LAST OTHER RMINATION (Mo., Year)	NLY 14. EDUCAT (Specify only Elementary)S NNCY PRENAT DATE ((Month)	TION TION Thighest grade completed) TAL 20. TOTAL PRENAT VISITS TITIS B YES NO HEPATITIS B GIVEN VDay/Year)
11. HISPANIC ORIGIN (Yes or No) 15. EXPECTED SERVICES 17a. MEDICAL MOTHER 21. (Do no 21a. NOW LIVIN Number None 22a. MOTHER YI If yes enter name	12. ANCESTRY - South America Arab, English, Engl	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispe, French, Finnish, etc. (sy YMENT FOR MEDICAL edicate, etc.) R OF 17b. MEDICAL CHILD 21c. DATE OF BIRTH (Mc	ENTIAL IN Cuben, Central anic, Afro-Americ pacity setow) 16. MOTH RECORD NUM LAST LIVE a, Year) 22b, INFANT	HER'S MA MBER OF 21d. O (Sponiar after con Nun Non TRANSFI	IATION FOR CON 3. RACE - American Indian nationality, ie., Chinese, (specify below) AlLING ADDRESS (street Matter 18. PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADDRESS (street Matter) BERRED? NO cility transferred to:	MUNIT Black, Wr Filipino, As smbar, City or N 21e. DA TE	Y HEALTH USE O ite etc. If Asian, give ian Indian, etc. Villege, State, Zip) 19. MONTH OF PREGNA CARE BEGAN TE OF LAST OTHER RMINATION (Mo., Year) NT ADMITTED TO NICU? YES NO	NLY 14. EDUCAT (Specify only Elementary'S NCY PRENAT DATE (Month) DID BA	TION TION This back of the partition o
11. HISPANIC ORIGIN (Yes or No) 15. EXPECTED SERVICES 17a. MEDICAL MOTHER 21. (Do no 21a. NOW LIVIN Number None 22a. MOTHER YI If yes enter name	12. ANCESTRY - South America Arab, English, Engl	CONFIDE Mexican, Puerto Rican, an, Chicano, other Hispe, French, Finnish, etc. (sy YMENT FOR MEDICAL edicate, etc.) R OF 17b. MEDICAL CHILD 21c. DATE OF BIRTH (Mc	ENTIAL INI Cuben, Central anic, Afro-Americ pacity selow) 16. MOTH RECORD NUM LAST LIVE b, Year) 22b, INFANT YE if yes enter no	HER'S MAMBER OF 21d. O (Spontar after con Num Non TRANSFI	IATION FOR CON 3. RACE - American Indian nationality, ie., Chinese, (specify below) AlLING ADDRESS (street Matter 18. PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADOPTIC PENDING ADDRESS (street Matter) BERRED? NO cility transferred to:	MUNIT Black, Wr Filipino, As 21e. DA TE 23. INFA IF YES (Y HEALTH USE O ite etc. If Asian, give ian Indian, etc. Villege, State, Zip) 19. MONTH OF PREGNA CARE BEGAN TE OF LAST OTHER RMINATION (Mo., Year) NT ADMITTED TO NICU? YES NO MONTH/Day/Year)	NLY 14. EDUCAT (Specify only Elementary'S NCY PRENAT DATE (Month) DID BA DATE (TION y highest grade completed) secondary (0-12) College (1-4) TAL 20. TOTAL PRENAT VISITS TITIS B YES NO HEPATITIS B GIVEN YDay/Year) ABY DIE? YES OF DEATH (Month/Day/Year) 27. APGAR SCORE

RAPID CORRECTION

31. MEDICAL RISK FACTORS FOR THIS PREGNANCY (Check all that apply)	36. ABNORMAL CONDITIONS OF THE NEWBORN (Check all that apply)
Anemia (HCT. <30/Hgb.<10)	Anemia (Hct<39/Hbg<13) 01
Cardiac disease 02	Birth Injury
Acute or chronic lung disease	Fetal alcohol syndrome
Diabetes 04	Hyaline membrane disease/RDS 04
Genital herpes 05	Meconium aspiration syndrome
Hydramnios/Oligohydramnios	Assisted ventilation <30 min
Hemoglobinopathy 07	Assisted ventilation >=30 min
Hypertension, chronic	Seizures
	None 09
Hypertension, pregnancy-associated 09	None
Eclampsia10	Other (Specify)10
Incompetent cervix	19 -
Previous infant 4000 + grams 12	
Previous preterm or small-for-gestational-age	
infant 13	SCREEN 3
Renal disease	
Rh sensitization	37. APPARENT CONGENITAL ANOMALIES OF
Uterine bleeding	NEWBORN (Check all that apply)
None	Anancanhalisa
None	Anencephalus
Other (Specify)18	Spina Bifida/Meningocele
Other (openity)	Hydrocephalus
	Microcephalus
33. OBSTETRIC PROCEDURES (Check all that apply)	Other central nervous system anomalies - CNS
Amniocentesis 19	(Specify) 15
Electronic fetal monitoring	
Induction of labor	Heart malformations
Stimulation of labor	Other circulatory/respiratory anomalies
Tocolysis	No. of the control of
Ultrasound	(Specify)17
None	
Other (Specify)26	Rectal atresia/stenosis
A4 COMPLICATIONS OF LABOR AND/OR DELINERY	atresia
 COMPLICATIONS OF LABOR AND/OR DELIVERY (Check all that apply) 	Omphalocele/Gastroschisis
Febrile (>100 F. or 38 C.) 01	(Specify) 21
Meconium, moderate/heavy 02	(opecity)21
Premature rupture of membrane (>12 hours) 03	Malformed genitalia
Abruptio placenta	Renal agenesis
Placenta previa	Other urogenital anomalies
Other excessive bleeding	outer an agrantan an annual agrantan ag
Seizures during labor	(Specify)24
Drecipitate labor (<2 hours)	
Precipitate labor (<3 hours)	SCREEN 4
Prolonged labor (>20 hours)	SCREEN 4
Dysfunctional labor	Cleft lip/palate01
Breech/Malpresentation	Polydactyly/Syndactyly/Adactyly
Cephalopelvic disproportion	Club foot
Cord prolapse	Diaphragmatic hernia 04
Anesthetic complications	Diaphraginatic nernia
Fetal distress	Other musculoskeletal/integumental anomalies
None	(Specify)05
Other (Specify) 17	
	Down's syndrome 06
35. METHOD OF DELIVERY (Check all that apply)	Other chromosomal anomalies
Vaginal 18	(Specify)07
Vaginal birth after previous C-section	None on □
Primary C-section 20	None
Repeat C-section	Other (Specify)09
Forceps	on to topolity
Vacuum 23	1



Completing the Newborn Screening Card

It is extremely important to fill out the Newborn Screening (NBS) Card completely and legibly.

Baby:

Name: Last name, first name Gender: Male or Female

Birth Date: Use (mm/dd/yy) for birth date

Birth Time: Use military time
Birth Weight: Record weight in grams

Gestational Weeks: Record week of gestation at the time of birth
Single Birth: Shade in oval to indicate this is a single birth
Multiple Birth Order: Shade in oval indicating order of birth (A, B, C, etc)

Specimen Date: Use (mm/dd/yy) for date the specimen is collected

Collection Time: Use military time for the time the specimen is collected

Collected By: Initials of person collecting the specimen

NICU/Special Care: Shade in oval if the newborn was in the NICU or special care nursery when the

specimen was collected

RBC Transfusion: Shade in oval if baby was transfused and record date (mm/dd/yy)

Medical Record #: Record the baby's medical record number

TPN Feeding: Shade in oval if infant received total parenteral nutrition (TPN) prior to specimen

collection

Ancestry: Shade in oval for "Hispanic" or "Non-Hispanic"

Race: Shade in oval for race. Mark "Non-White" parent if one parent is White, and

mark "multiracial" if both parents are Non-White

Mother:

Name: Last name, first name

Address: Mom's current street address, city, state and zip code

Phone: Area code and home telephone number

Social Security #: Record mom's social security number (SS#) but if mom has no SS# enter 9's all

the way across the field indicating SS# was not forgotten

Medical Record #: Record mom's medical record number Birth Date: Use (mm/dd/yy) for mom's birth date

Hepatitis B Surface Antigen (HBsAg):

Use (mm/dd/yy) for date mom is tested, and shade in positive or negative results.

If there is no HBsAg test results in chart, test mom STAT.

Physician:

Name: Last name, first name

Phone: Area code and physician's office telephone number

Submitter:

Name: Last name, first name Hospital Code: Hospital ID code number

Address: List current street address, city, state and zip code

Phone: Area code and telephone number

Birth Hospital: Name of birth hospital

(This form is a condensed version of the original document. To view the entire document, go to http://www.michigan.gov/documents/NewCardInstructions_70647_7.pdf).

23



Can Hepatitis B Surface Antigen-Positive Women Breastfeed?

Women infected with the hepatitis B virus often raise the question about the risk of infection to their infants from breastfeeding. The Perinatal Hepatitis B Prevention Program uses the following sources as reference:

1) The Red Book, American Academy of Pediatrics, 2006 Report of the Committee on Infectious Diseases "Transmission of Infectious Agents via Human Milk" p.125

"Hepatitis B surface antigen (HBsAg) has been detected in milk from HBsAg-positive women. However, studies from Taiwan and England have indicated that breastfeeding by HBsAg-positive women does not increase significantly the risk of infection among their infants. In the United States, infants born to known HBsAg-positive women should receive Hepatitis B Immune Globulin (HBIG) and the recommended series of 3 doses of hepatitis B virus vaccine, effectively eliminating any theoretic risk of transmission through breastfeeding. There is no need to delay initiation of breastfeeding until after the infant is immunized. Immunoprophylaxis of infants with hepatitis B virus vaccine alone also provides protection, but optimal therapy of infants born to HBsAg-positive mothers includes HBIG and the 3-dose series of hepatitis B virus vaccine."

2) Vaccinate Women, Winter 2002: A periodical for obstetrician/gynecologists from the Immunization Action Coalition, Volume 1, Number 1, p.1.

In the column "Ask the Experts" Harold Margolis, MD, and Linda Moyer, RN gave the following information.

Q: "Is it safe for an HBsAg-positive mother to breast-feed her infant?"

A: "Yes! An HBsAg-positive mother who wishes to breastfeed should be encouraged to do so, including immediately following delivery. However, the infant should receive HBIG and hepatitis B vaccine within 12 hours of birth. Although HBsAg can be detected in breast milk, studies done before hepatitis B vaccine was available showed that breastfed infants born to HBsAg-positive mothers did not demonstrate an increased rate of perinatal or early childhood HBV infection. More recent studies have shown that among infants receiving postexposure prophylaxis to prevent perinatal HBV infection, there is no increased risk of infection among breastfed infants."

- 3) Vaccinate Women, August 2004: A periodical for obstetrician/gynecologists from the Immunization Action Coalition, Volume 3, Number 1, p.1.
- **Q:** "What is the possibility of maternal transmission of hepatitis B virus (HBV) when breast-feeding an infant if the mother is HBsAg-positive and has cracked or bleeding nipples?"
- **A:** "Although HBsAg can be detected in breast milk, there is no evidence that HBV can be transmitted by breast-feeding. In studies done before hepatitis B vaccine was available, similar rates of mother-to-infant transmission were found among breast-fed and formula-fed infants. These findings indicate that the risk of transmission from breast-feeding is negligible, if any, compared with the high risk of infant exposure to maternal blood and body fluids at birth. More recent studies have shown that among infants receiving postexposure prophylaxis to prevent perinatal HBV infection, there is no increased risk of infection among breast-fed infants.

Babies born to HBV-infected mothers should be immunized with hepatitis B vaccine and hepatitis B immune globulin (HBIG), which will substantially reduce the risk of perinatal transmission. In addition, immunization should protect the infant from modes of postnatal HBV transmission, including possible exposure to HBV from cracked or bleeding nipples during breast-feeding. To prevent cracked and bleeding nipples, all mothers who breast-feed should be instructed on proper nipple care.

Vaccine Storage Basics

1. Keep the refrigerator/freezer plugged in and cold

- 1. Refrigerators should have separate, sealed refrigerator & freezer compartments
- 2. Have separate temperature controls for refrigerator & freezer compartments
- a. Put certified thermometers in the refrigerator and in the freezer
- b. Check and record the temperature in the refrigerator & freezer twice daily
- c. Use a safety plug or plug cover to prevent accidental disconnection
- d. Place "DO NOT UNPLUG" warnings near the outlet and circuit breaker
- e. Keep water bottles in refrigerator and ice packs in freezer

2. Keep these vaccines in the refrigerator (35° – 46° F or 2° – 8° C)

DTaP, Tdap, Td, DT	HPV4	PCV7
Hib	MMR*	PPV23
IPV	MCV4	TIV
Hep A	MPSV4	
Hep B	Rota	

a. Put them in the refrigerator as soon as they arrive

3. Keep these vaccines frozen (5°F or -15°C or lower)

Varicella LAIV MMR* Zoster MMRV

a. Put them in the freezer as soon as they arrive

4. Keep vaccines protected from light

a. Remove individual dose vials from cardboard package only as needed

5. Do not allow vaccine to expire

- a. Check expiration dates monthly
- b. Place vaccines so those that will expire first are used first
- c. Stock only what you can use in 1–2 months
- d. For VFC vaccine: call your local health department VFC contact person if any of your VFC vaccine will expire in less than 6 months

6. Transport vaccines correctly

- a. Refrigerated vaccines must be transported in an insulated cooler with a barrier separating the vaccines from the ice/cold packs
- b. Place a thermometer in the cooler to monitor the temperature
- c. Frozen vaccines can only be transported in an insulated cooler with dry ice
- d. Place vaccines appropriately in the refrigerator or freezer immediately upon arrival at the clinic

^{*}MMR vaccine can be stored in the refrigerator or the freezer



Eligibility and Ordering Protocol: Hepatitis B Vaccine and Hepatitis B Immune Globulin for Infants and Contacts of Hepatitis B Surface Antigen-Positive Women

Summary:

Hepatitis B (hepB) vaccine and hepatitis B immune globulin (HBIG) are available on an as-needed basis for administration in private provider offices, hospitals, local health departments, health centers, and clinics for the care of those clients currently enrolled in the Perinatal Hepatitis B Prevention Program (PHBPP).

Eligibility for those currently enrolled in the PHBPP:

HepB vaccine and HBIG:

• Infants born to hepatitis B surface antigen-positive (HBsAg-positive) women

HepB vaccine:

• Susceptible household and sexual contacts of HBsAg-positive women

HBIG*:

- Susceptible household and sexual contacts of HBsAg-positive women should receive HBIG within 7 days of an identifiable blood exposure.
- Susceptible sexual contacts of acutely HBsAg-positive women should receive HBIG within 14 days of a sexual exposure.

Infants born to HBsAg-positive women should receive 3 doses of single-antigen hepB vaccine at 0, 1-2 and 6 months of age. If using hepB-containing combination vaccines, give a single-antigen dose of hepB vaccine within 12 hours of birth and complete the series with doses at 2, 4 and 6 months of age if using PediarixTM; or with doses at 2, 4, & 12-15 months of age if using Comvax®. Post-vaccination serology should be done at 9-18 months of age (3 months after the completion of the hepB vaccine series). Susceptible household and sexual contacts of HBsAg-positive women should receive 3 doses of hepB vaccine on a schedule of 0, 1 and 4-6 months with post-vaccination serology 1-2 months after the completion of the vaccine series.

HepB Vaccine/HBIG Orders:

All private providers, hospitals, health centers, and clinics may order hepB vaccine from their local health department (LHD). The LHD can place orders through the Michigan Department of Community Health (MDCH) Biologic Distribution office either by faxing a request to 517-335-9039 or by calling 517-335-9040. Requests for HBIG should be forwarded to the PHBPP.

Private Providers, Hospitals, Health Centers, and Clinics:

Whenever hepB vaccine and/or HBIG are administered to eligible infants or contacts in the PHBPP a *Hepatitis B Perinatal Case Report-Infant/Contact* Form (DCH-0973, pg 19 of the Perinatal Hepatitis B Manual) should be completed and forwarded to the PHBPP Case Manager. Private providers, hospitals, health centers, and clinics should account for the hepB vaccine they have administered on the *VFC Programs Vaccine Doses Administered Reporting Form*. These forms should be submitted to the LHD.

Local Health Departments:

Whenever hepB vaccine and/or HBIG are administered by a LHD to eligible infants or contacts in the PHBPP a *Hepatitis B Perinatal Case Report-Infant/Contact* Form (DCH-0973, pg 19 of the Perinatal Hepatitis B Manual) should be completed and forwarded to the PHBPP Case Manager. LHDs should account for the hepB vaccine they have administered on the *VFC Programs Vaccine Doses Administered Reporting Form*. The LHDs should also account for hepB vaccine and HBIG on the *Local Health Department Monthly Vaccine Inventory Report*. The Michigan Care Improvement Registry (MCIR) or other software packages may be used to produce similar reports. These forms should be mailed monthly to the MDCH Division of Immunization or faxed to 517-335-9855.

For additional information, please call the PHBPP program staff at 517-335-8122 or 800-964-4487. In southeast Michigan, call 313-456-4431 or 313-456-4432.

26 Rev 08/15/06

^{*}Suggested intervals between immune globulin preparations and live virus vaccines are 3 months.

Special Purpose Michigan VFC/Immunization Programs

Universal Hepatitis B Vaccination Program for Newborns

To encourage the immunization of **all** newborns with the birth dose of hepatitis B vaccine before discharge from the hospital, MDCH makes vaccine available to hospitals for all newborns, regardless of VFC status. The *Universal Hepatitis B Vaccination Program for Newborns - Hospital Enrollment Form* (Section II - Pages 13-15) is used to enroll birthing hospitals in this component of the VFC Program and must be updated and submitted annually. Assessment of VFC eligibility is required to comply with federal regulations. However, the vaccine is available for **all** newborns, regardless of VFC status. Screening of infants who receive hepatitis B vaccine through the Universal Hepatitis B Vaccination Program may be accomplished by having each child's eligibility status (Medicaid, uninsured, American Indian/Alaskan Native, underinsured, insured) documented somewhere in their medical record. If this documentation already exists in the record, additional screening is not needed. For example, if the child is enrolled in Medicaid or a private health plan, a photocopy of their health plan card in the chart is sufficient. For children who are uninsured or American Indian/Alaskan Native, documentation of these eligibility criteria in the chart is adequate.

Hospitals are required to report hepatitis B vaccinations to the Michigan Care Improvement Registry (MCIR). The easiest way to submit this data is to note the immunization on the electronic birth certificate (EBC). The data may also be provided to the MCIR by other methods.

VACCINES FOR CHILDREN (VFC) PROGRAM Universal Hepatitis B Vaccination Program for Newborns -Hospital Enrollment Form Year 2006/2007 Page 1 of 3

VFC PIN # (Required)	
(For Local Health Department Use Only)	

Please Type or Pri	int						
Name of Hospital:							
Physician:	Name						
Last	Name		First				M.I.
Shipping Address:_							
	Street	Suite #		City			Zip
Mailing Address:							
(if different)	Street	Suite #		City			Zip
Telephone: ()						
Area C	ode	Area	Code				
Contact Name:							
	Last Name		First				M.I.
Medical License #:		Medicaid Pro	ovider #:_				
ls your hospital a:	Federally Qualified Rural Health Cent	d Health Center (FQHC)* er (RHC)*	□ Ye	s s		No No	
* FQHCs and RHCs a	are health care clinics	that have applied for and red	ceived fed	deral app	prov	al to ser	ve medically

To participate in the Universal Hepatitis B Vaccination Program for Newborns and receive federally procured vaccine at no cost, I, on behalf of the hospital listed above and all the practitioners, nurses, and others associated with this health delivery facility, agree to do the following:

- 1. Administer VFC vaccines only to newborns in accordance with the immunization schedule, dosages and contraindications established by the Advisory Committee on Immunization Practices (ACIP) and the VFC resolutions issued by the ACIP. Any exceptions these guidelines practice must be based on: a) the attending physician's medical judgment, in accordance with accepted medical practice; or b) a reasonable belief that a specific requirement contradicts the law in my state pertaining to religious or other exemptions.
- 2. Maintain medical records pertaining to the Universal Hepatitis B Vaccination Program for Newborns for a period of at least 3 years. If requested, the hospital named above will make such records available to the local health department, the state or the Department of Health and Human Services (DHHS).
- 3. Provide eligibility information in each child's medical record (see Section II Page 6 for more details).
- 4. Provide a current Vaccine Information Statement (VIS) that includes the Michigan Care Improvement Registry (MCIR) statement and maintain records in accordance with the National Childhood Vaccine Injury Act (NCVIA).
- 5. Not impose a charge for the cost of the vaccine.

under-served populations using federal grant funds.

6. Not impose a charge for the administration of the vaccine that is higher than the maximum fee of \$16.75 per injection as established by DHHS.

VACCINES FOR CHILDREN (VFC) PROGRAM Universal Hepatitis B Vaccination Program for Newborns - Hospital Enrollment Form Year 2006/2007 Page 2 of 3

- 7. Report hepatitis B immunizations of any newborn immunized at the hospital directly to the Michigan Care Improvement Registry (MCIR) via the electronic birth certificate (EBC) worksheet.
- 8. Use the State's *Official Certificate of Immunization* (green immunization record card) or a printed record from the MCIR to record doses of vaccine administered for the patient's personal record.
- 9. Not deny administration of a federally procured vaccine to a child because the child's parent, guardian, or individual of record is unable to pay the administration fee.
- 10. Comply with state and local health department requirements for ordering vaccine.
- 11. Comply with the Centers for Disease Control and Prevention's (CDC) Recommendations for Handling and Storage of Vaccines. In the event that vaccines obtained through the programs are wasted due to expiration, negligence and/or improper vaccine storage and handling practices, the hospital will reimburse the Michigan Department of Community Health (MDCH) for the replacement cost of vaccines wasted.
- 12. Allow the local health department to conduct a CDC-based VFC site visit, including access to 30 patient charts for a review of immunization documentation and eligibility screening. Agree to work with the local health department to implement any corrective actions as a result of the site visit.
- 13. Follow appropriate vaccine management procedures such as submitting regular doses administered reports to the local health department, maintaining accurate thermometers and appropriate temperatures in refrigerators and freezers where vaccine is stored, monitoring refrigerator and freezer temperatures twice daily in units where vaccine is stored, and notifying the local health department when state-supplied vaccine has wasted or will expire within three months.
- 14. Document according to *Statute 42 US Code 300aa-25* and CDC requirements (see Section II, page 22).

The hospital may terminate this agreement at any time. The State may terminate this agreement at any time if I fail to comply with these requirements. Upon termination, the hospital agrees to return all publicly provided vaccines to the local health department.

Physician (Please print or type Physician's name)	Title (MD, DO)
	<u> </u>
Physician's signature	Date

VACCINES FOR CHILDREN (VFC) PROGRAM Universal Hepatitis B Vaccination Program for Newborns - Hospital Enrollment Form Year 2006/2007 Page 3 of 3

Eligibility Criteria

This document provides shipping information and is used to develop annual population estimates that are submitted to the Centers for Disease Control and Prevention (CDC) and used by CDC to determine Michigan's annual allocation of federal funds. The form is also used to compare estimated vaccine needs with actual vaccine supply.

Profile Table: The following information must be based on data rather than estimates and should reflect the number of children expected to be born in a year. Please document the data source.

Number of

Rirthe

	5 ,		Births	ı
Enrolled in Me	dicaid			
Uninsured				
American India	an/Alaskan Native			
Underinsured/	Fully insured/Private Pay (incl	ludes MI-Child)		
ANNUAL TOT	ALS			
Data source used to determine profile (please check all that apply): Registry Data (MCIR) PREFERRED Medicaid Claims Data Provider Encounter Data Tally Sheet Vaccine Replacement Data Doses Administered Data Prior Ordering Data Other (Specify)				
Clinic/Site Deliv	ery Hours:			
Monday Tuesday Wednesday Thursday Friday	AM to AM to AM to AM to AM to AM to		PM PM PM PM	to to to to

September 1, 2006

Section II - Page 30

Resource Book For VFC Providers

Countries with Moderate or High Rates of Hepatitis B

(Greater than 2% of the population is HBsAg positive for Hep B)

Afghanistan French Polynesia Sevchelles Malawi Albania Gabon Malaysia Sierra Leone Algeria Gambia, The Maldives Singapore American Samoa Georgia Mali Slovakia Ghana Solomon Islands Angola Malta Antigua & Barbuda Greece Marshall Islands Somalia Armenia Grenada Martinique South Africa Guadeloupe Mauritania Spain Azerbajan St. Kitts and Nevis Bahrain Guam Mauritius Bangladesh Guatemala Micronesia, FSM St. Lucia Benin Guinea Sudan Moldova Bhutan Guinea-Bissau Mongolia Suriname Morocco Botswana Guyana Swaziland Haiti Syrian Arab Republic Brazil Mozambique Brunei Honduras Myanmar Taiwan Namibia Tajikistan Bulgaria Hong Kong Burkina Faso Nepal Tanzania, United Rep. India Burundi Indonesia **Netherlands Antilles** Thailand New Caledonia Togo **Byelorus** Iran Cambodia (Kampuchea) Iraq Niger Tonga Cameroon Israel Nigeria Tunisia Cape Verde Northern Marinia Turkey Italy Cayman Islands Oman Turkmenistan Jamaica Central African Republic Pakistan Uganda Japan Chad Ukraine Jordan Palau Papau New Guinea United Arab Emirates China Kazakhstan Paraguay Comoros Kenya UNRWA Congo, Peoples Republic Kirgyzstan Peru Uzbekistan Cook Islands Kiribati **Philippines** Vanuatu Cote d'Ivoire Korea, Peoples (DPR) Poland Venezuela Czechloslavakia Korea, Republic of Portugal Vietnam Virgin Islands, U.S. Diibouti Kuwait Puerto Rico **Dominica** Laos Qatar Wallis and Futuna Dominican Republic Yemen Latvia Reunion Ecuador Lebanon Romania Yemen Dem Egypt, Arab Republic of Russia Yugoslavia Lesotho **Equatorial Guinea** Zaire Liberia Rwanda Estonia Libya Samoa, Western Zambia

Lithuania

Madagascar

Macau

Ethiopia

French Guiana

Fiji

Sao Tome & Principe

Saudi Arabia

Senegal

Zimbabwe

Free immunization brochures and materials order form

Order these materials online at http://www.hpclearinghouse.org

If you prefer, you may fax this order form to (517) 699-2376. For information about orders that have already been placed, call the Michigan Department of Community Health (MDCH) Clearinghouse toll-free at (888) 76-SHOTS. Any other questions should be directed to the MDCH Division of Immunization (517) 335-8159.

Please enter quantity for each requested item. (Orders for brochures are usually limited to 500, unless otherwise stated. Limits on orders may be temporarily decreased if inventory is low.)

Quantity needed	Item requested
(Limit 1)	2007 Alliance for Immunization in Michigan (AIM) Provider Tool Kit – (Updated annually) This packet is designed for health care professionals who administer vaccines to their patients. Immunization schedules for children, adolescents and adults are included, along with information about contraindications, administration, documentation, and storage and handling of vaccines.
(Limit 1,000)	Adult Immunization Record Card
(Limit 50)	Influenza Vaccination Pocket Guide – (the pocket guides are for health care providers ONLY)
(Limit 50)	Pneumococcal Polysaccharide (PPV23) Vaccination Pocket Guide – (for health care providers)
Quantity needed	Brochures
	Protect Babies and Toddlers from Serious Diseases – UPDATED in 2006
	(formerly called the Immunize Your Little Michigander brochure)
	Keep Your Family Safe from the Flu – UPDATED for 2006-2007 flu season
	If you have Diabetes, Getting a Flu Shot is a Family Affair
	Shots for your Child (about the Vaccines for Children program)
	Are you 11-19 years old? Then you need to be protected – UPDATED (Please note: An updated brochure will be available in early 2007.)

Quantity needed	Brochures				
	accine Safety – What parents need to know				
	(Please note: An updated brochure will be available in 2007.)				
	Adult Immunizations – Are you protected?				
	Hepatitis B: What Parents Need to Know (With special information for pregnant women)				
	(Please note: An updated brochure will be available in 2007.)				
	The Dangers of Hepatitis B: What they are, How to avoid them				
	Hepatitis, What you need to know (ABCs)				
	Antibiotics: What You Should Know				
	To order: aterials may be ordered online at http://www.hpclearinghouse.org is form may also be faxed to the MDCH Clearinghouse at (517) 699-2376				
Name:					
Type of Clinic/practice:	□ Pediatric □ Family Practice □ Adult/Internal Med □ OB/GYN □ Specialty				
Email address*	:				
Street address*	Street address*:				
City: State: MI** Zip code:					
Phone no.: (include area code)					
*Complete email ac	ddress to receive immunization information updates.				
** Reminder: We c	annot ship to P.O. boxes. ** Materials are available to Michigan residents only.				
	n or for special requests, contact the Michigan Department of Community Health, ration (517) 335-8159.				



Immunization Materials

Order Date:		

To order, complete the shipping information below, then indicate the quantity of each item you desire. Where possible, the latest revision date for an item is given. **NOTE:** Private providers, mail your order to your local county health department. Local county health departments, mail/fax your order to the Division of Immunization, Michigan Department of Community Health, 201 Townsend Street, PO Box 30195, Lansing, MI 48909; fax number: 517-335-9855. **Orders cannot be shipped to a PO Box.**

Organization	Contact Person
Street Address	Phone Number (include area code)
City	Zip Code

FORMS			
Quantity		Quantity	
	Health Appraisal Form (6-2001) OCAL-3305		Official Certificate of Immunization - Wallet Size (3-2005) DCH-0592
	Immunization Materials Order Form (5-2005) DCH-0487		Perpetual Inventory Record Card (8" x 5") (2-2002) DCH-1117
	Immunization Signature Record Card (7-2005) DCH-0606		Perpetual Inventory Record Sheet (5-91) DCH-0607
	Mich. School Bldg. Weekly Report for Communicable Disease (3-2005) DCH-0453		Vaccine Administration Record (9-94) IP-95
	MOMS Reminder Card (General) (1-96) IP-12		Vaccine Adverse Event Reporting System VAERS-1
	MOMS Reminder Card (Tots) (1-96) IP-12A		

PERINATAL HEPATITIS B MATERIALS (Call 517-335-8122 to order hepatitis B forms)			
Quantity		Quantity	
	Alert Stickers IP-83		Perinatal Case Report (Contact & Infant) (8/05) DCH-0973
	Important Cards		"Mothers — Don't share hepatitis B" Cards

VACCINE INFORMATION STATEMENTS (VIS) ON NEXT PAGE

VACCINE INFORMATION STATEMENTS (VISS)

All Vaccine Information Statements are available in the languages shown unless otherwise noted. Please indicate the number of VIS sheets you require in each language desired. All English VISs are available ONLY in packages of 250. All translations may have the same version date as the English version. The following VISs are available in the indicated languages.

same version date as the English ve	ersion. The following VISs are available in the indicated languages.
	English (E), Albanian (AL), Arabic (AR), Armenian (A), Bosnian (B), Burmese (BU)
	Cambodian (CA), Chinese (C), Croation (Serbian) (CR), Farsi (FA), French (F), German (G),
LANGUAGE	Haitian Creole (HC), Hindi (HI), Hmong (H), Ilokano (IL), Italian (I), Japanese (J), Korean
KEY 🎏	(K), Laotian (L), Marshallese (M), Polish (PO), Portuguese (P), Punjabi (PU), Romanian (RO),
	Russian (RU), Samoan (SA), Serbo-Croatian (SC), Somali (SO), Spanish (S), Tagalog (T), Thai
	(TH), Turkish (TU), Vietnamese (V)
Chickenpox	Available in: All except M
DTaP	Available in: All except M
Hib	Available in: All except M
Hepatitis A	Available in: All except BU, M
Hepatitis B	Available in: All except M
Influenza	Available in: All except AR, BU, G, M, RO, SA
Japanese Encephalitis	Available in E
MMR	Available in: All languages
Meningococcal	Available in: E, HC, PO, RU, SO, S, TH, TU
Pneumococcal Conjugate	Available in: All except BU, M
Pneumococcal Polysaccharide	Available in: E, CA, C, HC, H, L, RU, SO, S, TH, TU, V
Polio	Available in: All except BU, M
Rabies	Available in: E, S
Rotavirus	Available in: E, S, TH
Smallpox	Available in: E, CA, H, L, RU, SC, SO, S, V
Td	Available in: All except BU, M
Tdap	Available in: E, S
Typhoid	Available in: E, S
Yellow Fever	Available in: E, S

To order VIS in the desired language, please indicate how many of each language you need. Example: For Chickenpox – 250 E, 100 S, 25 J = Equals: 250 English, 100 Spanish & 25 Japanese. **Please PRINT clearly.**

1 · · · · · · · · · · · · · · · · · · ·	and the second s	
Chickenpox		
DTaP		
Hib		
Hepatitis A		
Hepatitis B		
Human Papillomavirus (E, S, TH Only)		
Influenza		
MMR		
Meningococcal		
Pneumococcal Conjugate		
Pneumococcal Polysaccharide		
Polio		
Rabies		
Rotavirus		
Smallpox		
Shingles (English Only)		
Td		
Tdap		
Typhoid		
Yellow Fever		
DCH-0487	30 Rev. 11	12/06



Web Sites for Hepatitis Resources

GENERAL INFORMATION	
American Academy of Pediatrics	<u>www.aap.org</u>
Centers for Disease Control & Prevention (CDC)	<u>www.cdc.gov</u>
CDC Morbidity and Mortality Weekly Report (MMWR)	
Immunization Action Coalition (IAC)	<u>www.immunize.org</u>
IAC (vaccine information)	www.vaccineinformation.org
Immunization Gateway	www.immunofacts.com
Michigan Occupational Safety and Health Administration (MIOSHA)	www.michigan.gov/miosha
MIOSHA Standards for Bloodborne Pathogens www.michigan.gov/documents/CI	
Parents of Kids w/Infectious Diseases (PKIDS)	
Partnership for Prescription Assistance	www.pparxmi.org
Patient Advocate Foundation	www.patientadvocate.org
Vaccine Safety	-
World Health Organization (WHO)	
HEPATITIS INFORMATION	
American Gastroenterological Association	www.gastro.org
American Liver Foundation	
Asian Liver Center	
CDC Hepatitis Information	-
Clinical Trial Information	
Hepatitis and Intravenous Drug Use	
Hepatitis B Foundation (Liver Specialists)	
Hepatitis B Info Page	_
Hepatitis B Recommendations: "A Comprehensive Immunization Strategy to Elim	
B Virus Infection in the United States"www.cdc.gov/mmwr/pre	
Hepatitis B support information	
Hepatitis C Info Page	The state of the s
Hepatitis C Connection	
Hepatitis Foundation International	
Hepatitis Support Project	
HIV and Hepatitis Site	
Janis and Friends Hepatitis C Support	
Massachusetts Hepatitis Patient Empowerment Project	
Michigan Hepatitis C Foundation	www.mia-neppep.org
North American Society for Pediatric Gastroenterology, Heptology, and Nutrition	
Perinatal Hepatitis B Program Manual	
	. www.michigan.gov/nepatiusb
PHARMACEUTICAL COMPANIES	
Amgen	
Bristol-Myers Squibb Company	
Glead	
GlaxoSmithKline	
MedImmune	
Merck and Co., Inc	
North American Biologics, Inc	
Novartis	
Roche Pharmaceuticals	
sanofi pasteur	
Schering-Plough	
Wyeth-Lederle Vaccines and Pediatrics	<u>www.ahp.com</u>

31 Rev 08/15/06

Recommended Immunization Schedule for Ages 0-6 Years UNITED STATES • 2007

Birth HepB	1 month	2 months	4 months	6 months	12 months	15	18	19–23	2–3	4–6	
НерВ	He				months	months	months	months	years	years	
	- 110	рВ	see footnote 1		He	pB		Н	epB Seri	es	Range of recommended
		Rota	Rota	Rota							ages Catch-up
		DTaP	DTaP	DTaP		DI	aP			DTaP	immunization
		Hib	Hib	Hib⁴	Hi	ib		Hib			Certain high-risk grou
		PCV	PCV	PCV	PC	CV					
		IPV	IPV		IP	V	I			IPV	
						Influe	nza (Yea	rly)			
					MIN	ИR				MMR	
					Vario	cella				Varicella	
						HepA (2 doses)		НерА	Series	
									MPS	SV4	
			DTaP Hib PCV	DTaP DTaP Hib Hib PCV PCV	DTaP DTaP DTaP Hib Hib Hib' PCV PCV PCV	DTAP DTAP Hib Hib Hib' H PCV PCV PCV PCV IPV IPV IP NI	DTAP DTAP DTAP DT Hib Hib Hib' Hib PCV PCV PCV PCV IPV IPV IPV Influe MMR Varicella	DTaP DTaP DTaP Hib Hib Hib Hib Hib PCV PCV PCV PCV IPV IPV Influenza (Yeal	DTaP DTaP DTaP Hib Hib Hib Hib Hib Hib PCV PCV PCV IPV IPV Influenza (Yearly) MMR	DTaP DTaP DTaP Hib Hib Hib' Hib Hib PCV PCV PCV PCV PIPV IPV IPV Influenza (Yearly) MMR Varicella HepA (2 doses) HepA	DTaP DTaP DTaP DTaP Hib Hib Hib Hib Hib PCV PCV PCV PCV PPV IPV IPV IPV IPV Influenza (Yearly) MMR Varicella Varicella

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children through age 6 years. For additional information see www.cdc.gov/nip/recs/child-schedule.htm. Any dose not administered at the recommended age should be administered at any subsequent visit when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components

of the combination are indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective ACIP statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at www.vaers.hhs.gov or by telephone, 800-822-7967.

1. Hepatitis B vaccine (HepB). (Minimum age: birth)

At birth:

- Administer monovalent HepB to all newborns prior to hospital discharge.
- If mother is HBsAg-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB within 12 hours of birth.
 Determine the HBsAg status as soon as possible and if HBsAg-positive, administer HBIG (no later than age 1 week).
- If mother is HBsAg-negative, the birth dose can only be delayed with physician's order and mothers' negative HBsAg laboratory report documented in the infant's medical record.

Following the birth dose:

• The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1–2 months. The final dose should be administered at age ≥24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of 3 or more doses in a licensed HepB series, at age 9–18 months (generally at the next well-child visit).

4-month dose of HepB:

 It is permissible to administer 4 doses of HepB when combination vaccines are given after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed.

2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)

- Administer the first dose between 6 and 12 weeks of age. Do not start the series later than age 12 weeks.
- Administer the final dose in the series by 32 weeks of age. Do not administer a
 dose later than age 32 weeks.
- There are insufficient data on safety and efficacy outside of these age ranges.

3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)

- The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
- · Administer the final dose in the series at age 4-6 years.

4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks)

- If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
- TriHiBit® (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in ≥12 months olds.

- 5. Pneumococcal vaccine. (Minimum age: 6 weeks for Pneumococcal Conjugate Vaccine (PCV); 2 years for Pneumococcal Polysaccharide Vaccine (PPV))
 - Administer PCV at ages 24-59 months in certain high-risk groups. Administer PPV to certain high-risk groups aged ≥2 years. See MMWR 2000; 49(RR-9):1-35.
- 6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine (TIV); 5 years for live, attenuated influenza vaccine (LAIV)
 - All children aged 6–59 months and close contacts of all children aged 0–59 months are recommended to receive influenza vaccine.
 - Influenza vaccine is recommended annually for children aged ≥59 months with certain risk factors, healthcare workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006: 55(RR-10):1-41.
 - For healthy persons aged 5-49 years, LAIV may be used as an alternative to TIV.
 - Children receiving TIV should receive 0.25 mL if aged 6–35 months or 0.5 mL if aged ≥3 years.
 - Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV).

7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)

Administer the second dose of MMR at age 4–6 years. MMR may be administered prior to age 4–6 years, provided ≥4 weeks have elapsed since the first dose and both doses are administered at age ≥12 months.

8. Varicella vaccine. (Minimum age: 12 months)

Administer the second dose of varicella vaccine at age 4–6 years. Varicella vaccine may be administered prior to age 4–6 years, provided that ≥3 months have elapsed since the first dose and both doses are administered at age ≥12 months. If second dose was administered ≥28 days following the first dose, the second dose does not need to be repeated.


9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)

- HepA is recommended for all children at 1 year of age (i.e., 12–23 months).
 The 2 doses in the series should be administered at least 6 months apart.
- · Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
- HepA is recommended for certain other groups of children including in areas where vaccination programs target older children. See MMWR 2006; 55(RR-7):1-23.

10. Meningococcal polysaccharide vaccine (MPSV4). (Minimum age: 2 years)

 Administer MPSV4 to children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high risk groups. See MMWR 2005;54 (RR-7):1-21.

Recommended Immunization Schedule for Ages 7–18 Years UNITED STATES • 2007



This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 7–18 years. For additional information see www.cdc.gov/nip/recs/child-schedule.htm. Any dose not administered at the recommended earlier age should be administered at any subsequent visit when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of

the combination are indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective ACIP statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at www.vaers.hhs.gov or by telephone, 800-822-7967.

FOOTNOTES

1. Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).

(Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL™)

- Administer at age 11–12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a Td booster dose.
- Adolescents 13–18 years who missed the 11–12 year Td/Tdap booster dose should also receive a single dose of Tdap if they have completed the recommended childhood DTP/DTaP vaccination series.

2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)

- Administer the first dose of the HPV vaccine series to females at age 11–12 years.
- Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose.
- Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.
- 3. Meningococcal vaccine. (Minimum age: 11 years for meningococcal conjugate vaccine (MCV4); 2 years for meningococcal polysaccharide vaccine (MPSV4))
 - Administer MCV4 at age 11–12-years and to previously unvaccinated adolescents at high school entry (\sim 15 years of age).
 - Administer MCV4 to previously unvaccinated college freshmen living in dormitories; MPSV4 is an acceptable alternative.
 - Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high risk groups. See MMWR 2005;54 (RR-7):1-21. Use MPSV4 for children aged 2–10 years and MCV4 or MPSV4 for older children.

4. Pneumococcal polysaccharide vaccine (PPV). (Minimum age: 2 years)

- Administer for certain high-risk groups. See MMWR 1997; 46(RR-08);
 1–24 and MMWR 2000; 49(RR-9):1-35.
- Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine (TIV); 5 years for live, attenuated influenza vaccine (LAIV)

- Influenza vaccine is recommended annually for persons with certain risk factors, healthcare workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006; 55(RR-10);1-41.
- For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
- Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV).

6. Hepatitis A vaccine (HepA). (Minimum age: 12 months)

- The 2 doses in the series should be administered at least 6 months apart.
- HepA is recommended for certain other groups of children including in areas where vaccination programs target older children. See MMWR 2006; 55(RR-7):1-23.

7. Hepatitis B vaccine (HepB). (Minimum age: birth)

- Administer the 3-dose series to those who were not previously vaccinated.
- A 2-dose series of Recombivax HB® is licensed for 11-15 year olds.

8. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)

- For children who received an all-IPV or all-oral poliovirus (0PV) series, a fourth dose is not necessary if third dose was administered at age ≥4 years.
- If both OPV and IPV were administered as part of a series, a total of 4 doses should be given, regardless of the child's current age.

9. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)

•If not previously vaccinated, administer 2 doses of MMR during any visit with ≥ 4 weeks between the doses.

10.Varicella vaccine. (Minimum age: 12 months)

- Administer 2 doses of varicella vaccine to persons without evidence of immunity.
- Administer 2 doses of varicella vaccine to persons aged ≤13 years at least 3 months apart. Do not repeat the second dose, if administered ≥28 days following the first dose.
- Administer 2 doses of varicella vaccine to persons aged ≥13 years at least 4 weeks apart.

Recommended Immunization Schedule for Children and Adolescents Who Start Late or Who Are More Than 1 Month Behind

The tables below give catch-up schedules and minimum intervals between doses for children who have delayed immunizations. There is no need to restart a vaccine series regardless of the time that has elapsed between doses. Use the table appropriate for the child's age.

CATCH-UP SCHEDULE FOR AGES 4 MONTHS THROUGH 6 YEARS									
Vaccine	Minimum Age		Minimum Interval Between	en Doses					
Vaccinc	for Dose 1	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5				
Hepatitis B¹	Birth	4 weeks	8 weeks (and 16 weeks after first dose)						
Rotavirus ²	6 wks	4 weeks	4 weeks						
Diphtheria,Tetanus, Pertussis³	6 wks	4 weeks	4 weeks	6 months	6 months ³				
Haemophilus influenzae type bʻ	6 wks	4 weeks if first dose given at age <12 months 8 weeks (as final dose) if first dose given at age 12-14 months No further doses needed if first dose given at age ≥15 months	4 weeks⁴ if current age <12 months 8 weeks (as final dose)⁴ if current age ≥12 months and second dose given at age <15 months No further doses needed if previous dose given at age ≥15 months	8 weeks (as final dose) This dose only necessary for children aged 12 months—5 years who received 3 doses before age 12 months					
Pneumococcal ⁵	or current age 24–59 months		4 weeks if current age <12 months 8 weeks (as final dose) if current age ≥12 months No further doses needed for healthy children if previous dose given at age ≥24 months	8 weeks (as final dose) This dose only necessary for children aged 12 months–5 years who received 3 doses before age 12 months					
Inactivated Poliovirus ⁶	activated Poliovirus ⁶ 6 wks 4 weeks 4 weeks		4 weeks	4 weeks ⁶					
Measles, Mumps, Rubella ⁷	12 mos	4 weeks							
Varicella ⁸	12 mos	3 months							
Hepatitis A ⁹	12 mos	6 months							

CATCH-UP SCHEDULE FOR AGES 7–18 YEARS									
Vaccine	Minimum Age	Minimum Interval Between Doses							
vaccine	for Dose 1	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5				
Tetanus, Diphtheria/ Tetanus, Diphtheria, Pertussis¹º	7 yrs¹º	4 weeks	8 weeks if first dose given at age <12 months 6 months if first dose given at age ≥12 months	6 months if first dose given at age <12 months					
Human Papillomavirus ¹¹	9 yrs	4 weeks	12 weeks						
Hepatitis A ⁹	12 mos	6 months							
Hepatitis B¹	Birth	4 weeks	8 weeks (and 16 weeks after first dose)						
Inactivated Poliovirus ⁶	6 wks	4 weeks	4 weeks	4 weeks ⁶					
Measles, Mumps, Rubella ⁷	12 mos	4 weeks							
Varicella ⁸	12 mos	4 weeks if first dose given at age ≥13 years							
	12 mos	3 months if first dose given at age <13 years							

DEPARTMENT OF HEALTH AND HUMAN SERVICES • CENTERS FOR DISEASE CONTROL AND PREVENTION • SAFER • HEALTHIER • PEOPLE

- 1. Hepatitis B vaccine (HepB). (Minimum age: birth)
 - Administer the 3-dose series to those who were not previously vaccinated.
 - A 2-dose series of Recombivax HB® is licensed for 11-15 year olds.
- 2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)
 - Do not start the series later than age 12 weeks.
 - · Administer the final dose in the series by 32 weeks of age. Do not administer a dose later than age 32 weeks.
 - There are insufficient data on safety and efficacy outside of these age ranges.
- 3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)
 - The fifth dose is not necessary if the fourth dose was administered at age ≥4 years.
 - DTaP is not indicated for persons aged ≥7 years.

4. Haemophilus influenzae type b conjugate vaccine (Hib).

(Minimum age: 6 weeks)

- Vaccine is not generally recommended for children aged ≥5 years.
- If current age <12 months and the first 2 doses were PRP-OMP (PedvaxHIB® or ComVax® [Merck]), the third (and final) dose should be administered at age 12-15 months and at least 8 weeks after the second dose.
- If first dose given at age 7-11 months, give 2 doses separated by 4 weeks plus a booster at age 12-15 months.
- 5. Pneumococcal conjugate vaccine (PCV). (Minimum age: 6 weeks) Vaccine is not generally recommended for children aged ≥5 years.
- 6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
 - For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if third dose was administered at age ≥4 years.
 - If both OPV and IPV were administered as part of a series, a total of 4 doses should be

given, regardless of the child's current age.

- 7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
 - The second dose of MMR is recommended routinely at age 4-6 years but may be administered earlier if desired.
 - If not previously vaccinated, administer 2 doses of MMR during any visit with ≥4 weeks between the doses.
- 8. Varicella vaccine. (Minimum age: 12 months)
 - The second dose of varicella vaccine is recommended routinely at age 4-6 years but may be administered earlier if desired.
 - Do not repeat the second dose in persons aged <13 years, if administered ≥28 days following the first dose.
- 9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
 - HepA is recommended for certain groups of children including in areas where vaccination programs target older children. See MMWR 2006; SS (RR-7) 1-23.

10. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).

(Minimum ages: 7 years for Td, 10 years for BOOSTRIX®, and 11 years for ADACEL™)

- •Tdap should be substituted for a single dose of Td in the primary catch-up series or as a booster if age-appropriate; use Td for other doses.
- A five-year interval from the last Td dose is encouraged when Tdap is used as a booster dose. A booster (4th) dose is needed if any of the previous doses were administered at age <12 months. Refer to ACIP recommendations for further information. See MMWR 2006; SS (RR-3) L34.
- 11. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)
- Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.

Is the vaccine safe?

The hepB vaccine is very safe. The most common side effect is soreness at the place where the shot was given.

Before babies are given the hepB vaccine, their parents should be given a form called Hepatitis B Vaccine, What You Need To Know. This form gives information about the vaccine. Parents are asked to read the form and then talk with the doctor or nurse if they have questions.

Should older children get the hep B vaccine?

All children and teenagers should get the hepB vaccine. Parents can talk to their children's doctor or nurse about getting the vaccine.

Should anyone else get the shots?

People should get the hepB vaccine if they:

- live with someone who has the hepatitis B virus
- have more than one sexual partner
- have a sexually transmitted disease
- are a hemodialysis patient
- get blood products
- have liver disease
- come into contact with blood at their jobs
- inject drugs

More information

For more information, call your child's doctor, local health department, or the Michigan Department of Community Health Perinatal Hepatitis B Prevention Program at 517-335-8122 or 800-964-4487. In southeast Michigan, call 313-456-4431 or 313-456-4432.

Websites

Michigan Department of Community Health www.michigan.gov/hepatitisb

Centers for Disease Control and Prevention (CDC)

www.cdc.gov/hepatitis

Immunization Action Coalition www.immunize.org

Hepatitis B Information and Support List www.hblist.org

PROTECT YOUR CHILDREN TODAY BY HAVING THEM GET THEIR HEPATITIS B SHOTS!

Michigan Department
of Community Health

Total

Jennifer M. Granholm, Governor
Janet Olszewski, Director


MDCH is an Equal Opportunity Employer, Services and Programs Provider. 30,000 printed at 3.9 cents each with a total cost of \$3,905.69.

Rev. 11/06



HEPATITIS B: What Parents Need to Know

With special information for pregnant women



What is hepatitis B?

Hepatitis B is a disease caused by a virus that infects the liver. People often show no signs of having the virus. Most people who get the virus get better in a few months, but some carry the virus in their blood all their lives (they are called carriers). In the United States, about 51,000 people get hepatitis B every year, and about one million people are carriers.

C

Babies can get hepatitis B at birth if their mother has the hepatitis B virus.



Babies and young children may also get hepatitis B if they come into contact with blood or body fluids from their mother or from people they live with who have hepatitis B. The younger you are when you get hepatitis B, the more likely you will become a carrier of the disease.

How do you get hepatitis B?

You can get it:



• at birth, if your mother has the virus

- by having sex or sharing needles with someone who has the virus
- by sharing personal things like razors and toothbrushes with a person who has the virus

One out of three people with the hepatitis B virus does not know how he or she got it.

How do you know if you have hepatitis B?

Hepatitis B can make you feel tired or sick and can sometimes make your skin and eyes yellow.

Many people don't know they have hepatitis B, because they don't feel or look sick. Even if you don't look or feel sick, you can still get liver disease and give hepatitis B to others.

The only way to know if you have hepatitis B is to get a blood test.



Women should be tested for hepatitis B surface antigen (HBsAg) during EACH pregnancy to see if they have the hepatitis B virus.

How can babies be safe from getting hepatitis B?

- If a test shows that a pregnant woman has the hepatitis B virus in her blood, her baby can get this virus at birth. Babies born to women who have the hepatitis B virus need:
 - hepatitis B immune globulin (HBIG) and hepatitis B (hepB) vaccine WITHIN TWELVE HOURS OF BIRTH
 - a second shot of hepB vaccine at one to two months of age
 - a third shot at six months of age
 - a blood test three to nine months after the last shot to make sure that they are safe from getting the hepatitis B virus

Babies born to women who do NOT have the hepatitis B virus should also get the hepB vaccine:

- starting at birth
- at one to two months of age
- on or after six months of age



MOTHERS...

Take this card with you when you go to the hospital. Give it to your nurse. This is one more way to help protect your baby from getting the hepatitis B virus.

Don't share hepatitis B with your baby.

You have the hepatitis B virus in your blood, and you could give this virus to your baby at birth. If your baby does get hepatitis B, he or she could become ill. Your baby could also give the virus to others.



How to protect your baby ...

Babies born to mothers who have the hepatitis B virus should get:

- Hepatitis B immune globulin (HBIG) and hepatitis B (hepB) vaccine within 12 hours of birth
- A second dose of hepB vaccine one-two months after the first dose
- A third dose at six months of age
- A blood test at nine to eighteen months of age (3 months after the completion of the vaccine series)

If you have questions about this program, or about how to get free hepB vaccine or free blood tests for your baby, household or sexual contacts, please call the Michigan Department of Community Health Perinatal Hepatitis B Program at 517-335-8122 or 800-964-4487. In southeast Michigan, call 313-456-4431 or 313-456-4432.

IMPORTANT!

Your baby got hepatitis B immune globulin (HBIG) and hepatitis B (hepB) vaccine on:



HBIG/	/	
	Date	
HepB vaccine		
	D	ate

Your baby needs at least two more doses of hepB vaccine. The next dose is due in one-two months. Please make an appointment as soon as you can, and record here as a reminder.

//		
Date	Time	
Doct	or/Clinic	

Please take this card and the baby's immunization record with you to your next appointment.

Note to baby's doctor on back:

To Health Care Providers:

All doses should be entered into the Michigan Care Improvement Registry (MCIR).

Recommended schedule for infants who are born to a hepatitis B surface antigen (HBsAg) positive woman:

Name of hospital				
Date of birth	/_ Date			
Name of infant Last	First		Mido	dle initial
And Antibody to hepatitis B surfaction (anti-HBs)	e	(Pos)	or	(Neg)
Hepatitis B surface antigen (H	HBsAg)	(Pos)		(Neg)
 Blood tests at 9-18 months of (3-9 months after the comple of the hepB vaccine series) 		/_	/_ Date	
 A dose of hepB vaccine at six months of age (and no soone 24 weeks of age) 		/_	/_ Date	
 A dose of hepB vaccine one-two months after the first (and no sooner than 4 weeks the first dose) 		/_	/_ Date	
 A dose of hepatitis B (hepB) vaccine within 12 hours of bir 	th	/	/ Date	<u>'</u>
(HBIG) within 12 hours of bir	rth	/	/ Date	<u></u>

If you have any questions, please call the Perinatal Hepatitis B Program at the Michigan Department of Community Health, Immunization Division, at 517-335-8122 or 800-964-4487. In southeast Michigan, call 313-456-4431 or 313-456-4432.



INDIVIDUAL IMMUNIZATION RECORD BRING THIS RECORD FOR IMMUNIZATIONS

NAME (Last, First, Middle) BIRTHDATE BIRTH NAME TYPE OF HEALTH PROFESSIONAL DATE GIVEN VACCINE VACCINE OR CLINIC DOSE DUE Mo/Day/Year 1 Diphtheria-2 Tetanus-Pertussis 3 (DTaP/DTP/DT/ 4 Td/Tdap) 5 6 7 8 9 1 Haemophilus Influenza type B 2 (Hib) 3 4 Hepatitis B 1 (HepB) 2 3 4 Polio (IPV/OPV) 2 3 4 1 Pneumococcal Conjugate 2 (PCV7) 3 4 1 Rotavirus (Rota) 2 Hepatitis A (HepA) 2 1 Measles-Mumps-Rubella (MMR) 1 Varicella (Var) Chickenpox 2 HX of chickenpox Meningococcal (MCV4/MPSV4) 1 Human Papillomavirus 1 (HPV4) 2 3 Zoster Shingles 1 Influenza (TIV/LAIV)** Other

^{*} Influenza vaccine recommendations change from year to year. Please check <u>www.michigan.gov/flu</u> for the most current changes, or call your local health department.

STATE OF MICHIGAN

OFFICIAL IMMUNIZATION RECORD

For Children and Adults

Name:	TOTAL DESCRIPTION OF THE PARTY	Sex:	□ F □ N	M
Birthdate:	1 The state of the			
Special Problems:	TUEBOR			
Physician/Clinic: _				
_	Name FOUNTRIS PERIOR SULLAM AND HIM		Telephone	
Parent/Guardian:	CIRCUMSPICE			
·	Name		Telephone	

Ages For Routine Childhood Vaccinations*

BIRTH 2 MONTHS 4 MONTHS 6 MONTHS **12-15 MONTHS** 18 MONTHS 4-6 YEARS 11-12 YEARS

*Alternative schedules are possible. Ask your doctor for details.

FOR MORE INFORMATION: www.michigan.gov/immunize or www.cdc.gov/nip

Getting immunized is a life-long job that prevents serious diseases.

- Children 11-12 years of age need shots to prevent tetanus, diphtheria, pertussis (whooping cough), and meningococcal disease. Girls should receive human papillomavirus vaccine.
- All adults (not just the elderly) need vaccines to protect them from severe illnesses.
- Many people need yearly influenza vaccine. Ask if you or one of your family members should get flu vaccine.

DCH-0592 (02/2007) Authority: Act 368 1978

Keep track of the immunizations you and your child have received.

- Bring your immunization card to every medical visit. This is necessary for children and adults.
- Ask to have your card updated every time vaccines are given.
- The Michigan Care Improvement Registry (MCIR) keeps immunization records for Michigan residents. Ask if the vaccine you or your child received is entered in MCIR.
- Children must meet Michigan's immunization requirements to enroll in any nursery, day care, preschool or head start program, and public or non-public school.



	Dose (units)	Type of vaccine		Date given mo/day/yr	Health professional or clinic	Date next dose due
Нер В			1			
			2			
			3			
Нер А			1			
			2			
If combo*			*			
	Com	bination vac	cine	s should always	be documented under each	n antigen.
MMR A second dos	e may be		1			
needed in sor	ne péople		2			
Varicella			1			
(chicken	oox)		2			
Zoster (s	hingles)		1			
Td, Tdap						
(Tetanus, diphtheri						
[pertussi						
	-		H			
			\vdash			
	1		Н			

ADULT IMMUNIZATION RECORD

Always carry this record with you and have your health professional or clinic keep it up to date.

Last name

<u>≺</u>

Birthdate:



	Type of vaccine	Date given mo/day/yr	Health professional or clinic	Date next dose due
Pneumococcal A second dose may be needed for those at risk.				
Influenza				
HPV (Human		1 2		
Papillomavirus)		3		
Meningococcal				
Other				
For more infor	rmation, call	your doctor, your loc	al health department, or 1-8	888-76-SHOTS.